Process for the iron-mediated nitrate reduction for the functionalization of anilines and aminoheterocycles
The iron-mediated nitrate reduction process generates fleeting diazonium intermediates for the functionalization of anilines and aminoheterocycles, addressing safety concerns and improving efficiency by preventing diazonium accumulation and enabling higher yields at ambient temperatures.
Patent Information
- Application Number
- PCT/EP2026/062272
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-07
- Filing Date
- 2026-04-28
- Publication Date
- 2026-11-12
AI Technical Summary
Existing methods for the functionalization of anilines and aminoheterocycles using diazonium salts are hazardous due to the accumulation of explosive diazonium compounds, and there is a need for a safer and more efficient one-step process that avoids diazonium accumulation.
A process utilizing iron-mediated nitrate reduction to generate fleeting diazonium intermediates through a compound pair of Fe(III) nitrate and a sulfur-oxygen reductant, followed by sulfochlorination, fluorination, or cyanation steps, allowing for the direct functionalization of aromatic or heteroaromatic primary amino compounds at ambient temperatures.
This method achieves safer and more efficient functionalization by preventing diazonium accumulation, enabling higher yields and broader substrate compatibility, including sterically hindered and electron-deficient compounds, while avoiding exothermic decomposition and nitrogen evolution.
Smart Images

Figure EP2026062272_12112026_PF_FP_ABST
Abstract
Description
[0001] Process for the Iron-Mediated Nitrate Reduction for the Functionalization of Anilines and Aminoheterocycles
[0002] The present invention refers to a process for the functionalization such as a deaminative chlorosulfonylation, deaminative fluorination or deaminative cyanation of an aromatic or heteroaromatic primary amino compound. With the inventive process, the iron-mediated in-situ nitrate reduction allows the direct functionalization of anilines and aminoheterocycles via an aryldiazonium or heteroaryl diazonium salt as a fleeting intermediate in solution.
[0003] Methods for the halogenation of aromatic cycles including deaminative halogenations have been reported before.
[0004] For example, DHERANGE BALLI D. ET AL: "Direct Deaminative Functionalization", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 145, no. 1 , 22 December 2022 (2022-12-22), pages 17-24, describe a method for the deaminative halogenation of amines. However, the reaction proceeds by isodiazene intermediates and not by diazonium salts. The isodiazene intermediates possess completely different chemical reactivity than diazonium salts. Therefore, the chemical transformations that can be achieved by the method disclosed in said reference are very different from the present process.
[0005] Furthermore, GHIAZZA CLEMENT ET AL: "Deaminative chlorination of aminoheterocycles", NATURE CHEMISTRY, vol. 14, no. 1 , 16 December 2021 (2021-12-16), pages 78-84 disclose a method for the deaminative chlorination of heteroaromatic amines. However, the reaction proceeds by pyridinium salts as intermediates, which again have completely different reactivity to diazonium salts. Moreover, the protocol only shows that deaminative chlorination, bromination, and fluorination, iodination reactions are not included.
[0006] EP 2 602 242 A 1 describes the deaminative functionalization of anilines via in situ generated diazonium salts with TEMPO as initiator for the diazotization. Although the process features the in situ generation of the diazonium salt, the diazotization is still carried out with nitrite-based reagents. Diazotization with nitrite reagents is very fast. Therefore the process still holds the risk of diazonium accumulation. It can therefore be not rendered as safer as in the case of protocol of the present invention. Moreover TEMPO is an unstable and expensive reagent which leads to much less utility than protocol of the present invention. The main feature of the protocol of the present invention is the combination ofslow nitrate reduction with diazotization and further functionalization. The rate-limiting nitrate reduction prevents the accumulation of diazonium salts.
[0007] There are further prior art documents dealing with processes making use of diazotizations steps. For example, Hoffmann R.V.: “m-trifluoromethylbenzenesulfonyl chloride”, Organic Syntheses vol. 60, 1 January 1981 (1981-01-01), page 121, discloses the preparation of m-trifluoromethylbenzenesulfonyl chloride, starting from a,a,a-trifluoro-m-toluidine. This prior art document is an example for the common way of diazonium preparation. The protocol describes a two step procedure, diazotization followed by functionalization, utilizing common nitrite reagents for the diazotization. In contrast, the method here is a one-step protocol that avoids diazonium accumulation and is therefore inherently safer. Additionally, the present diazonium formation is based on nitrate reduction. Thus, the entire mechanism for the formation of reactive species that are responsible for the diazonium generation is fundamentally different. Thus, the present method is inventive over the work disclosed in said reference.
[0008] Yu et al. (Continuous flow reactor for Balz-Schiemann reaction: a new procedure for the preparation of aromatic fluorides”, Tetrahedron Letters, Elsevier, Amsterdam, NL, vol. 54, no. 10, 2 January 2013 (2013-01-02), pages 1261-1263) report a two-stage continuous-flow implementation of the Balz-Schiemann reaction for the rapid preparation of aromatic fluorides. The methodology described by Yu is based on diazonium generation using common nitrite reagents. A safer Balz-Schiemann reaction is achieved by employing a flow set-up to directly convert the generated diazonium salt into the corresponding aryl fluoride. However, mechanistically, the nitrite-based diazonium formation is distinct from the nitratebased method used in the present application, as it still bears the risk of diazonium accumulation. Also, the translation into a one-step Balz-Schiemann reaction is not obvious, due to counterion incompatibility and required a significant improvement which supports the inventiveness of the method of the present invention.
[0009] The study of Mackman R. L. et al. (“Exploiting Subsite S1 of Trypsin-Like Serine Proteases for Selectivity: Potent and Selective Inhibitors of Urokinase-Type Plasminogen Activator” Journal of medicinal chemistry, American chemical society, US, vol. 44, no. 23, 6 October 2001 (2001-10-06), pages 3856-3871) describes optimization of small-molecule inhibitors of trypsin-like serine proteases, culminating in highly selective urokinase (uPA) inhibitors. In the synthetic route to one key intermediate the authors employ a classical two-step sequence to introduce a cyano group via an aryl diazonium intermediate. The aromaticamine is converted to the corresponding diazonium salt by nitrosation with nitrite under acidic diazotization conditions, and this isolated / formed diazonium species is then carried forward into a separate, subsequent cyanation step to install the aryl-CN unit. In other words, diazotization (amine — > ArN2+) and cyanation (ArN2+— > Ar-CN) are performed as distinct, sequential operations, with the diazonium salt generated using nitrite in the usual manner and the cyanation effected in a second, separate transformation. The study of Mackman is a common example for a two-step diazotization and Sandmeyer cyanation process. Due to the variety of different possible side reactions between cyanide and copper with the reagents used for the diazotization, translating the two-step process into a one-step deaminative cyanation for the present invention is not obvious and required significant optimization of the reaction conditions and reagents. The work of the present invention here demonstrates a careful balance, between the kinetics of all reactions that take part in the overall transformation, which allows a productive deaminative cyanation and prevents potential side reactions, such as the formation of cyanogen or HCN.
[0010] The study of Mateos Javier et al: (“Nitrate reduction enables safer aryldiazonium chemistry”, Science - author manuscript, vol. 385, no. 6694, 26 April 2024 (2024-04-26), pages 446-452) discloses a safer, one-step deaminative halogenation of anilines that avoids accumulation of aryldiazonium salts by generating them only fleetingly via nitrate reduction. Using thiosulfate or dihalocuprates as electron donors to reduce nitrate (the rate-limiting step), the protocol forms aryldiazonium intermediates in situ and immediately converts them to the corresponding aryl halides — thereby improving efficiency and markedly reducing explosion risk associated with diazonium buildup. Crucially, the nitrate reduction requires heating to 85 °C to proceed effectively. The result is a practical paradigm shift in diazonium chemistry: a direct, safer, and often higher-yielding deaminative halogenation from anilines. In the present application, the inventors have described the one-step diazotizationfunctionalization methodology based on nitrate reduction, which is significantly different, both in terms of employed reagents and mechanism, from the other prior art as detailed before. However, in the study of Mateos, the nitrate reduction process required a temperature of at least 85 °C. Due to the decreased solubility of gases at elevated temperatures, the direct translation of the methodology into reactions that involve gaseous reagents was not achieved. Therefore, a nitrate reduction protocol that proceeds at ambient temperatures had to be invented. The iron nitrate based nitrate reduction was found to proceed at temperatures as low as 23 °C, which enabled the direct deaminative sulfonylation. Iron nitrate is a common oxidant and not obviously compatible with the other reagents in the mixture, its use as a reductant for nitrate is also rather uncommon due to itsoxidative properties. Additionally, iron nitrate has never been employed in a deaminative transformation. Due to potential oxidation reactions of nucleophiles, such as cyanide, or the aniline substrate itself, iron nitrate (as a strong oxidant) is not an obvious choice as a reductant for nitrate. The development of suitable reaction conditions thus required a significant inventive step and extended optimization of the reaction conditions to allow a kinetically feasible deaminative transformation at ambient temperature. Iron nitrate is also not comparable with potassium nitrate, as KNO3 is just a simple nitrate salt, while iron nitrate is a coordination complex, that, due to the redox properties of iron, allows for nitrate reduction.
[0011] However, the prior art has not used any rate-limiting nitrate salt or nitrate ester reduction for the in situ generation of diazonium salts in a large scope.
[0012] Aryldiazonium salts have become a staple in organic synthesis since their discovery in 1858; their synthesis still follows the protocol developed in the 19thcentury. Due to the favorable reactivity that often cannot be achieved with other aryl(pseudo)halides, diazonium chemistry continues to grow. Facile extrusion of dinitrogen contributes to the desired reactivity but is also reason for safety concerns. Explosions have occurred since their discovery and still result in accidents with casualties that deter from the utility of aryldiazonium salts. Here we report a diazonium chemistry paradigm shift based on nitrate reduction that avoids diazonium accumulation. Because nitrate reduction is rate-limiting, aryldiazoniums are produced as fleeting intermediates, which results in a safer and often more efficient deaminative halogenation in a single step from anilines.
[0013] In the prior art, several attempts of using diazonium salts have been made. Sandmeyer used aryldiazonium salts 140 years ago to achieve the oxidative addition to d10metals for the synthesis of aryl halides. The reactivity of diazonium salts often surpasses that of other (pseudo)halides and is based on their high electrophilicity, low reduction potential of - 0.16 V versus (vs) standard calomel electrode (SCE), and formation of dinitrogen as a leaving group that enables challenging transformations such as single electron transferbased oxidative addition to main group elements. Therefore, diazonium salts are still prepared routinely both on laboratory scale and in industrial plants; and arylhalides are still commonly prepared from aryldiazonium salts.
[0014] Since the first report on aryldiazonium salt synthesis with nitrous acid, little has changed in their preparation. Nitrosonium (NO+) ions, formed through acidic degradation of nitrite-based reagents such as sodium- (NaNCh) or isoamylnitrite, react with anilines at low temperature, which is commonly required due to the instability of aryldiazonium salts above 5 °C. The resulting salts are either isolated, or accumulate for subsequent treatment with nucleophiles, sometimes at higher temperatures, in a separate second step. Reaction enthalpies of up to AH= - 84 kcal mol-1are common for diazonium decomposition reactions and can result in violent degradation. The often unpredictable stability of aryldiazonium salts can result in detonation upon contact with air and even in solution, which has led to a multitude of severe accidents in undergraduate lab courses, academic research, and industry, with fatal consequences at times. The persistent assumption in the community that the tetrafluoroborate (BF4") counterion prevents explosions of diazonium salts has been proven to be incorrect since BF4" salts have also been reported to explode.
[0015] To attenuate the risks associated with aryldiazonium batch processes, continuous flow set ups can be employed. Although several large scale processes are in place, such as the Balz-Schiemann reaction for the synthesis of fluorobenzene, small changes in the protocol, small quantities of impurities, or mechanical force can result in unexpected detonations, and every new aryldiazonium salt should be considered dangerous and explosive until proven otherwise. To mitigate the dangers associated with diazonium chemistry, alternative deamination protocols have been developed that, for example, employ pyridines as leaving groups or isodiazenes as intermediates, yet, those reactions typically do not achieve the broad utility and high atom economy of the parent diazotization methods.
[0016] Thus, there is the need to provide a process for functionalization such as sulfonylation, fluorination, or cyanation of an aromatic or heteroaromatic amino compound without the danger of using accumulated explosive diazonium compounds.
[0017] The problem of the present invention is solved by the provision of the inventive process as defined in the claims. In more detail, the present invention refers to a process for the functionalization of an aromatic or heteroaromatic primary amino compound wherein an aromatic or heteroaromatic primary amino compound is reacted with a compound pair of Fe(lll) nitrate and a sulfur oxygen reductant or mixtures thereof, whereby an aromatic or heteroaromatic-N2+-intermediate compound is provided, which is in situ further subjected to a reaction step selected from a sulfochlorination step, a fluorination step or a cyanation step.Preferably, the sulfur-oxygen reductant is selected from alkali or ammonium salts of thiosulfuric acid, thiosulfates, polythionates, dithionates, trithionates, tetrathionates, dithionites, sulfites, bisulfites, sulfur dioxide, or metabisulfites, or mixtures thereof.
[0018] In an embodiment of the invention, the aromatic or heteroaromatiic primary amino compound is selected from C5 to C20 aryl or heteroaryl primary amino compounds.
[0019] In a further embodiment, off the process for the functionalization of an aromatic or heteroaromatic primary amino compound, the reaction is carried out in an optionally aqueous polar aprotic solvent such as, but not limited to: acetonitrile, butyronitrile, ethylacetate, chloroform, 1,2-dichloroethane, dichloromethane, acetone, or mixtures thereof.
[0020] In the inventive process, said aromatic or heteroaromatic-N2+-intermediate compound may be further reacted in a sulfochlorination step with SO2 in the presence of a Cu(l) or Cu (II) salt or complex and a chloride source whereby a chlorosulfonylated aromatic or heteroaromatic compound is obtained. The copper (I) or (II) salt or complex may be CuCI, or CuCh. The chloride source may be an alkali metal or metal salt, or a mineral acid, such as HCI.
[0021] In the inventive process, said aromatic or heteroaromatic-N2+-intermediate compound may be further reacted in a fluorination step with a fluorination agent whereby a fluorinated aromatic or heteroaromatic compound is obtained. Said fluorination agent may be selected from metal salts such as a silver, an ammonium or an alkali salt of tetrafluoroboric acid, hexafluorophosphoric acid or hexafluoroantimonic acid.
[0022] In the inventive process, said aromatic or heteroaromatic-N2+-intermediate compound may also be further reacted in a cyanation step with a Cu(l) or Cu (II) salt or complex and a cyanide source whereby a cyanated aromatic or heteroaromatic compound is obtained. The copper (I) or (II) salt or complex may be CuCN. The cyanation agent may be selected from metal cyanides such as alkali cyanides.
[0023] As detailed throughout the present application the present invention allows the functionalisation of an aromatic or heteroaromatic primary amino compound by providing the intermediate diazonium compound by using compound pair of Fe(lll) nitrate and a sulfuroxygen reductant or mixtures thereof so that the formed intermediate compound can be further provided with substituents.
[0024] In said compound pair, the sulfur-oxygen reductant may be selected from alkali or ammonium salts of thiosulfuric acid, thiosulfates, polythionates, dithionates, trithionates, tetrathionates, dithionites, sulfites, bisulfites, sulfur dioxide, or metabisulfites, or mixtures thereof.
[0025] The inventive method is preferably carried out at room temperature up to an elevated temperature, optionally at the boiling point of the solvent, usually in the range of 20°C to 120°C. The polar organic solvent is not particularly critical and is preferably selected from the group consisting of polar aprotic solvents such as, but not limited to: acetonitrile, butyronitrile, ethylacetate, chloroform, 1,2-dichloroethane, dichloromethane, acetone, or mixtures thereof, optionally in combination with water up to 50 vol.-% of the liquid phase.
[0026] For the inventive method, the process can be carried out under an ambient atmosphere or in a closed container. The process can be carried out under a protective atmosphere such as nitrogen, argon or mixtures thereof, but there is no need in view of the reactions partners.
[0027] In the context of the aspects of the present invention, the following definitions are more general terms which are used throughout the present application.
[0028] When a range of values is listed, it is intended to encompass each value and sub-range within the range. For example “C1-6” is intended to encompass, Ci, C2, C3, C4, C5, Ce, C1-6, C1-5, C1-4, C1-3, C1-2, C2-6, C2-5, C2-4, C2-3, C3-6, C3-5, C3-4, C4-6, C4-5, and Cs-6.
[0029] The term “aliphatic” includes both saturated and unsaturated, straight chain ( / .e., unbranched), branched, acyclic, cyclic, or polycyclic aliphatic hydrocarbons, which are optionally substituted with one or more functional groups. As will be appreciated by one of ordinary skill in the art, “aliphatic” is intended herein to include, but is not limited to, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, and cycloalkynyl moieties. Thus, the term “alkyl” includes straight, branched and acyclic alkyl groups. An analogous convention applies to other generic terms such as “alkenyl”, “alkynyl”, and the like. Furthermore, the terms “alkyl”, “alkenyl”, “alkynyl”, and the like encompass both substituted and unsubstituted groups. In certain embodiments, “lower alkyl” is used to indicate those alkyl groups (acyclic, substituted, unsubstituted, branched or unbranched) having 1-6 carbon atoms.As used herein, “alkyl” refers to a radical of a straight-chain, branched or cyclic saturated hydrocarbon group having from 1 to 20 carbon atoms (“C1-20 alkyl”). In some embodiments, an alkyl group has 1 to 10 carbon atoms (“C1-10 alkyl”). In some embodiments, an alkyl group has 1 to 9 carbon atoms (“C1-9 alkyl”). In some embodiments, an alkyl group has 1 to 8 carbon atoms (“C1-8 alkyl”). In some embodiments, an alkyl group has 1 to 7 carbon atoms (“C1-7 alkyl”). In some embodiments, an alkyl group has 1 to 6 carbon atoms (“C1-6 alkyl”). In some embodiments, an alkyl group has 1 to 5 carbon atoms (“C1-5 alkyl”). In some embodiments, an alkyl group has 1 to 4 carbon atoms (“C1-4 alkyl”). In some embodiments, an alkyl group has 1 to 3 carbon atoms (“C1-3 alkyl”). In some embodiments, an alkyl group has 1 to 2 carbon atoms (“C1-2 alkyl”). In some embodiments, an alkyl group has 1 carbon atom (“Ci alkyl”). In some embodiments, an alkyl group has 2 to 6 carbon atoms (“C2-6 alkyl”). Examples of C1-6 alkyl groups include methyl (Ci), ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), iso-butyl (C4), n-pentyl (C5), 3-pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5), and n-hexyl (Ce). Additional examples of alkyl groups include n-heptyl (C7), n-octyl (Cs) and the like. Unless otherwise specified, each instance of an alkyl group is independently unsubstituted (an “unsubstituted alkyl”) or substituted (a “substituted alkyl”) with one or more substituents. In certain embodiments, the alkyl group is an unsubstituted C1-10 alkyl {e.g., -CH3). In certain embodiments, the alkyl group is a substituted C1-10 alkyl.
[0030] In the inventive process, any aromatic or heteroaromatic primary amino compound having 5 to 30 carbon atoms, optionally having side chains with up to 20 carbon atoms, and optionally up to three heteroatoms selected from O, S or N in the ring structure can be used as starting material, said ring structure having at least one primary amino substituent group on the aromatic or heteroaromatic ring system which primary amino substituent group can be reacted to a diazo group and subsequently replaced by a halogen. Said halogen can be any of Cl, Br or I and may be simply added, depending on the halogen, to the solution in the form of an alkali or ammonium salt, as halogen, or as an halogen alkyl compound such as 1,2-dichloroethane, 1,2-dibromoethane or 1,2-diiodoethane.
[0031] Said aromatic or aryl refers to a radical of a monocyclic or polycyclic {e.g., bicyclic or tricyclic) 4n+2 aromatic ring system e.g., having 6, 10, or 14 pi electrons shared in a cyclic array) having 6-14 ring carbon atoms and zero heteroatoms provided in the aromatic ring system (“Ce-14 aryl”). In some embodiments, an aryl group has six ring carbon atoms (“Ce aryl”; e.g., phenyl). In some embodiments, an aryl group has ten ring carbon atoms (“C10aryl”; e.g., naphthyl such as 1-naphthyl and 2-naphthyl). In some embodiments, an aryl group has fourteen ring carbon atoms (“Cuaryl”; e.g., anthracyl). “Aryl” also includes ring systems wherein the aryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the radical or point of attachment is on the aryl ring, and in such instances, the number of carbon atoms continue to designate the number of carbon atoms in the aryl ring system. Unless otherwise specified, each instance of an aryl group is independently optionally substituted, i.e., unsubstituted (an “unsubstituted aryl”) or substituted (a “substituted aryl”) with one or more substituents. In certain embodiments, the aryl group is unsubstituted Ce-14 aryl. In certain embodiments, the aryl group is substituted Ce-14 aryl.
[0032] “Aralkyl” is a subset of alkyl and aryl and refers to an optionally substituted alkyl group substituted by an optionally substituted aryl group. In certain embodiments, the aralkyl is optionally substituted benzyl. In certain embodiments, the aralkyl is benzyl. In certain embodiments, the aralkyl is optionally substituted phenethyl. In certain embodiments, the aralkyl is phenethyl.
[0033] “Heteroaryl” preferably refers to a radical of a 5-14 membered monocyclic or bicyclic 4n+2 aromatic ring system {e.g., having 6 or 10 pi electrons shared in a cyclic array) having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-14 membered heteroaryl”). In heteroaryl groups that contain one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits. Heteroaryl bicyclic ring systems can include one or more heteroatoms in one or both rings. “Heteroaryl” includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the point of attachment is on the heteroaryl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heteroaryl ring system. “Heteroaryl” also includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more aryl groups wherein the point of attachment is either on the aryl or heteroaryl ring, and in such instances, the number of ring members designates the number of ring members in the fused (aryl / heteroaryl) ring system. Bicyclic heteroaryl groups wherein one ring does not contain a heteroatom e.g., indolyl, quinolinyl, carbazolyl, and the like) the point of attachment can be on either ring, i.e., either the ring bearing a heteroatom {e.g., 2— indolyl) or the ring that does not contain a heteroatom {e.g., 5— indolyl).In some embodiments, a heteroaryl group is a 5-10 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-10 membered heteroaryl”). In some embodiments, a heteroaryl group is a 5-8 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-8 membered heteroaryl”). In some embodiments, a heteroaryl group is a 5-6 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-6 membered heteroaryl”). In some embodiments, the 5-6 membered heteroaryl has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heteroaryl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heteroaryl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur. Unless otherwise specified, each instance of a heteroaryl group is independently optionally substituted, i.e., unsubstituted (an “unsubstituted heteroaryl”) or substituted (a “substituted heteroaryl”) with one or more substituents. In certain embodiments, the heteroaryl group is unsubstituted 5-14 membered heteroaryl. In certain embodiments, the heteroaryl group is substituted 5-14 membered heteroaryl.
[0034] Exemplary 5-membered heteroaryl groups containing one heteroatom include, without limitation, pyrrolyl, furanyl and thiophenyl. Exemplary 5-membered heteroaryl groups containing two heteroatoms include, without limitation, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Exemplary 5-membered heteroaryl groups containing three heteroatoms include, without limitation, triazolyl, oxadiazolyl, and thiadiazolyl. Exemplary 5-membered heteroaryl groups containing four heteroatoms include, without limitation, tetrazolyl. Exemplary 6-membered heteroaryl groups containing one heteroatom include, without limitation, pyridinyl. Exemplary 6-membered heteroaryl groups containing two heteroatoms include, without limitation, pyridazinyl, pyrimidinyl, and pyrazinyl. Exemplary 6-membered heteroaryl groups containing three or four heteroatoms include, without limitation, triazinyl and tetrazinyl, respectively. Exemplary 7-membered heteroaryl groups containing one heteroatom include, without limitation, azepinyl, oxepinyl, and thiepinyl. Exemplary 5,6— bicyclic heteroaryl groups include, without limitation, indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzoisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzthiazolyl, benzisothiazolyl, benzthiadiazolyl, indolizinyl, and purinyl. Exemplary 6,6-bicyclic heteroaryl groups include, without limitation, naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl.
[0035] The present invention is further illustrated by the attached Figures and Examples. In the Figures, it is shown:
[0036] Fig. 1
[0037] (A) Structure of cd1 nitrite reductase NirS (PDB = 6TSI) with structure of heme d1; Structures of bioinspired catalysts for nitrate reduction.
[0038] (B) Conversion of diazonium salts presented by Landsberg and Meerwein and deaminative halogenation at 85 °C by Ritter.
[0039] (C) This work; direct deaminative sulfonylation and fluorination enabled by iron nitrate reduction at 25 °C
[0040] Figure 2 - Mechanism of the deaminative chlorosulfonylation.
[0041] (A) Deaminative chlorosulfonylation with iron nitrate at 25 °C; yields determined by1H NMR spectroscopy
[0042] (B) Nitrate reduction with thiosulfate at 23 °C, detection of NO2 by gas phase IR spectroscopy.
[0043] (C) Mechanistic overview for deaminative sulfonylation; Transition state of nitrate reduction
[0044] Fig. 3 - Different transformations for diversification after deaminative sulfonylation Standard conditions (SC): 0.500 mmol reduced flutamide 1, 0.500 mmol Na2S2O3-5H2O, 0.500 mmol Fe(NO3)3■ 9H2O, 0.500 mmol CuCI, 2.5 mL MeCN, 1.0 mmol HCI (4.0 M in 1,4-dioxane), 5.00 mmol SO2 (3.00 M in MeCN) at 40 °C for 16 h; a) SC; b) SC, then 2.00 mmol NH3(0.50 M in 1,4-dioxane) at 23 °C for 1 h; c) SC, then 2.00 mmol / V-acetylethylenediamine at 23 °C for 1 h; d) SC, then 0.500 mmol Troxipid and 0.500 mmol K2CO3at 23 °C for 2 h, e) SC, then 1.00 mmol CsF at 23 °C for 1 h; f) SC, then 10 equiv. H2O and 2.0 equiv. K2CO3at 85 °C for 16 h
[0045] Fig. 4 - Aniline scope for the deaminative chlorosulfonylation.
[0046] Products isolated as sulfonamides with pyrrolidine as nucleophile. Reaction conditions = 0.500 mmol aniline / amino heterocycle, 0.500 mmol Na2S2O35H2O, 0.500 mmol Fe(NO3)3■ 9H2O, 0.500 mmol CuCI, 2.5 mL MeCN, 1.0 mmol HCI (4.0 M in 1,4-dioxane), 5.00 mmol SO2 (3.00 M in MeCN) at 40 °C for 16 h; then 2.00 mmol pyrrolidine at 23 °C for 1 h.aisolated on 0.1 mmol scale.bisolated on 10 mmol scale.cisolated as sulfonyl chloride.Fig. 5 - Aniline scope for the direct deaminative fluorination.
[0047] Reaction conditions = 0.500 mmol aniline / amino heterocycle, 0.600 mmol Na2S2C>3-5H2O, 1.50 mmol NaSbFe, 1.00 mmol Fe(NOs)3 ■ 9H2O, 0.625 mL n-PrCN, 0.625 mL n-pentane, at 60 °C for 16 h (a) isolated on 0.1 mmol scale (b) yield determined by1H NMR spectroscopy due to the volatility of compound (c) AgSbFe used instead of NaSbFe.
[0048] Figure 6 - Scope of anilines and amino heterocycles for the deaminative cyanation.
[0049] Reaction condition is as follows: 0.500 mmol aniline, 1.00 mmol Fe(NO3)3'9H2O, 1.00 mmol CuCN, 0.600 mmol Na2SOs, 1.25 ml of acetonitrile, 70 °C, 12 hours. (a) 0.500 mmol aniline, 1.00 mmol Fe(NO3)3'9H2O, 1.00 mmol CuCN, 0.600 mmol Na2S2C>4, 1.25 ml of butyronitrile, 70 °C, 12 hours. Supplementary materials provide detailed experimental procedures
[0050] The inventors started their work with deliberations concerning a nitrate reduction strategy. According to said considerations, the formation of NCV in acidic conditions and the kinetic stability of NOs-may be the reasons that nitrate salts and their esters have been ignored as diazotization reagents over more than a century. The conversion of NC>2“ to NO+, and of NO3- to NO2+with acid are redox neutral processes. Use of nitrate (N oxidation state = +V) as diazotization reagent therefore requires a reductive pathway in the absence of strong acid for the generation of NO+(N oxidation state = +III). Single electron reduction to nitrogen dioxide (NO2, N oxidation state = +IV) allows the formation of NO+through dimerization and then disproportionation of dinitrogen tetroxide (N2O4). The inventor's protocol relies on sulfur-oxygen reductants which may be selected from alkali or ammonium salts of thiosulfuric acid, thiosulfates, polythionates, dithionates, trithionates, tetrathionates, dithionites, sulfites, bisulfites, sulfur dioxide, or metabisulfites, or mixtures thereof as electron donors for nitrate reduction and can employ readily available iron (III) nitrate. Although NOs-is thermodynamically strong enough to oxidize nucleophiles like bromide and iodide based on reduction potentials, it is compatible with various nucleophiles in the same reaction mixture, including bromide, iodide, and thiosulfate. In contrast, the hitherto used nitrite and alkylnitrites are incompatible with several nucleophiles because they react by kinetically facile oxidation. Therefore, such nucleophiles cannot be present during diazotization with nitrites; and diazoniums accumulate or must be isolated, which results in the safety issues of global diazonium chemistry.
[0051] Because the process of nitrate reduction is the rate-limiting step in the inventor's strategy, diazoniums are produced as fleeting intermediates in only minute concentrations, whichresults in several fundamental advantages when compared to the conventional diazonium chemistry employed over the past 150 years: i) exothermic decomposition and fast nitrogen evolution of aryldiazoniums is avoided, ii) anilines are used as starting materials directly, which avoids a two-step sequence with isolation or storage of diazonium salts, iii) most aryldiazoniums are unstable above 5 °C, therefore, conventional reactions are generally restricted to low temperature reactions, yet, the inventor's protocol is not limited by such a constraint and may access reaction chemistry beyond traditional diazonium reactions, and iv) nitrate and its esters are more readily available and less expensive than alkylnitrites. In addition, diazotization and functionalization of aryldiazoniums produce H2O and N2 as byproducts, as compared to other, modern deaminative strategies with pyridines, carboxylates, or esters as side products.
[0052] As shown by the present invention, nitrate reduction with iron nitrate at 25 °C allows to lower the overall reaction temperature and therefore to increase the amount of dissolved SO2. When the deaminative chlorosulfonylation was carried out with iron nitrate and thiosulfate at 25 °C, 67% of the desired sulfonyl chloride 1 was obtained, with only 6% of concomitant aryl chloride 2 (Fig. 2, A). The inventors understand that the deaminative chlorosulfonylation proceeds via aryldiazonium salts as fleeting intermediates (Fig. 2, C). NO2 formed via the nitrate reduction process can dimerize to form N2O4, which subsequently disproportionates to generate nitrosonium cation (NO+) and nitrate, as previously described. Diazonium salts are then generated by reaction of aniline with NO+following the conventional diazotization mechanism. The aryldiazonium reacts with CuCI, SO2 and HCI to form the sulfonyl chloride via initial formation of an aryl radical under the release of dinitrogen. When the deaminative chlorosulfonylation was carried out with 2-(allyloxy)aniline as radical trap, the respective radical cyclization product was detected, which is consistent with a radical mechanism operating. Additionally, control experiments were carried out in the absence of CuCI or HCI, which resulted in significantly lower yields of sulfonyl chloride when 4-aminobenzonitrile was used as substrate (21% yield without CuCI, 46% yield without HCI, Nitrate reduction can thus be utilized for the direct generation of aryl radicals from anilines.
[0053] Reaction optimization with 4-aminobenzonitrile 1a revealed that a combination of 1.0 equiv. iron nitrate with 1.0 equiv. Na2S2C>3-5H2O in the presence of 1.0 equiv. CuCI, and 2.0 equiv. HCI in 1,4-dioxane with an excess of SO2 (10 equiv.) in MeCN may lead to the formation of sulfonyl chlorides in high yield. An excess of SO2 was preferred, due to competing direct chlorination by conventional Sandmeyer chlorination. Stoichiometric iron nitrate was employed reducing co-factors that may be considered are often more expensive than ironnitrate and could interfere with the reaction chemistry. Development of a similar reaction with iron as a catalyst and an inexpensive co-factor for reduction is an exciting future challenge. CuCI can be used as a catalyst, also on larger scale. However, stoichiometric CuCI delivered higher yields for a broader range of substrates. For the chlorosulfonylation, HCI in 1,4-dioxane can be substituted with TMSCI. At 25 °C reaction temperature, reproducibility issues were encountered regarding the yield for the chlorosulfonylation to 1. The deaminative chlorosulfonylation gives the desired sulfonyl chloride 1 in 67% yield at 25 °C. It was empirically found that increasing the temperature to 40 °C, resolved the reproducibility issues and enabled slightly higher yields for a broader range of substrates, while avoiding higher temperatures at which direct Sandmeyer chlorination becomes problematic.
[0054] The produced sulfonyl chlorides can be further converted to other sulfonic acid derivatives by subsequent addition of nucleophiles (Fig. 3). Purification of the sulfonyl chloride after deaminative chlorosulfonylation is not required. However, aqueous workup before addition of the nucleophile is recommended to achieve satisfactory yields, presumably due to interactions between nucleophile and iron or copper salts in the reaction mixture when no aqueous workup is carried out before nucleophile addition.
[0055] The iron nitrate reduction proceeds with electron rich, electron neutral, and electron deficient anilines; also amino heterocycles were converted into the respective sulfonyl chlorides. Due to the ease of purification, the products were isolated as the pyrrolidine derived sulfonamides (Fig. 4). Substrates for which the isolation or accumulation of the respective diazonium salt would be problematic, such as heterocycles (13, 29, and 33), sterically hindered anilines (24), or complex anilines (32, and 34), were functionalized using the iron nitrate reduction strategy. Anilines of which the corresponding diazonium salts are explosive, such as nitroarenes (16), pyridines (13), or benzoic acid derivatives (15), can be functionalized, which demonstrates a safer access to the sulfonyl chlorides compared to the functionalization of isolated or accumulated diazonium salts.
[0056] The inventors observed that electron-deficient substrates generally result in facile sulfonyl chloride formation, while complex anilines that contain electron-donating groups typically give yields <30%. The deaminative chlorosulfonylation was scaled up to 10 mmol to give 18 in 59% yield (compared to 76% yield on 0.5 mmol scale, Fig. 4).The inventors previously demonstrated nitrate-based deaminative halogenation reactions, which remained limited to chlorination, bromination, and iodination. The discovery of the beneficial effect of iron for nitrate reduction allowed for preliminary data to now also include the remaining halide. Deaminative fluorination of anilines was achieved and demonstrated for several different aniline substrates (Fig. 5), further underlining the utility of the iron nitrate based protocol. The deaminative fluorination was carried out on sterically hindered anilines (36) and amino heterocycles (39) (Fig. 5). The inventors propose that the Fe-mediated nitrate reduction proceeds analogously to the deaminative sulfonylation reaction, producing NO2, which can generate an aryldiazonium intermediate. The resulting diazonium salt can subsequently react with SbFe" following a conventional Balz-Schiemann mechanism.
[0057] When aqueous HCI was used instead of HCI in organic solvents, lower yields of sulfonyl chloride may be obtained. With a large excess of water present, anilines are directly converted to the respective sulfonic acids.
[0058] Materials and Methods
[0059] All air- and moisture-insensitive reactions were carried out under ambient atmosphere and monitored by thin-layer chromatography (TLC). High-resolution mass spectra were obtained using Q Exactive Plus from Thermo. Concentration under reduced pressure was performed by rotary evaporation at 25-40°C at an appropriate pressure. Purified compounds were further dried under high vacuum (0.010-0.005 mbar). Yields refer to purified and spectroscopically pure compounds, unless otherwise stated.
[0060] Solvents
[0061] Acetonitrile was purchased from Fisher Scientific. Anhydrous solvents were obtained from Phoenix Solvent Drying Systems. All deuterated solvents were purchased from Euriso-Top. Chromatography
[0062] Thin layer chromatography (TLC) was performed using EMD TLC plates pre-coated with 250 pm thickness silica gel 60 F254 plates and visualized by fluorescence quenching under 254 nm UV light or permanganate stain. Flash chromatography was performed using silica gel (40-63 pm particle size) purchased from Geduran®.
[0063] Electrochemistry
[0064] For analytical experiments, a BASI™ epsilon E2 device was used in combination with a BASI Cell Stand C3, purchased from Bioanalytic systems Inc. For cyclic voltammetry a MF-2013 electrode (99.95 % Pt, 1.6 mm diameter) from Bioanalytic systems Inc. was used as working electrode. Potentials were measured versus a Ag / AgCI / NaCI(aq) (3 M) reference electrode, MF-2052 electrode RE-5B form Bioanalytic systems Inc.EPR Spectroscopy
[0065] Room temperature CW EPR measurements were carried out at X-band (-9.45 GHz) on a Bruker Magnettech™ ESR5000 benchtop spectrometer equipped with a temperaturecontrol system. A 100 kHz modulation frequency with an amplitude of 0.25 mT was used with a microwave power of -18 mW. Each scan over the field range (187-487 mT) spectra were recorded for 180 s and were accumulated if needed. A digital RC filter with a time constant of 500 ms, implemented on ESR5000, was applied to the raw data. Both postprocessing treatments were performed without artificial signal distortion. The spectra after smoothing with the Savitzky-Golay moving averages and correcting the baseline with the use of “garlic" function of Easyspin , MATLAB toolbox was used for further analysis.
[0066] NMR Spectroscopy
[0067] NMR spectra were recorded on a Bruker AVANCE III HD 500 spectrometer operating at 500 MHz, 471 MHz, and 126 MHz, for1H,19F, and13C acquisitions, respectively; a Bruker AVANCE NEO 600 spectrometer equipped with a cryogenically cooled cryoBBO probe operating at 600 MHz and 61 MHz for1H and15N acquisitions, respectively; or on a Bruker AVANCE III HD 400 spectrometer operating at 400 MHz, 100 MHz, 29 MHz, and 54 MHz for1H,13C,14N, and17O acquisitions, respectively.1H and13C Chemical shifts are reported in ppm with the solvent residual peak as the internal standard. For1H NMR: CDCh, 67.26; DMSO-cfe, 62.50; CD3CN, 5 1.94; For13C NMR: CDCh, 677.2; DMSO-cfe, 639.5; CD3CN, 5 1.3. Data is reported as follows: s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, m = multiplet, br = broad; coupling constants in Hz; integration.14N and15N shifts are reported relative to MeNO2 (5 = 0 ppm).17O shifts are reported relative to D2O (5 = 0 ppm). NMR shifts of heteronuclei were referenced using their respective E value using the xiref au program in Bruker Topspin following IIIPAC recommendations.
[0068] Computational details
[0069] All calculations were performed using a development version of the ORCA program package based on version 5.0. Geometry optimizations, transition-state locations, and enthalpy and free energy computations at standard conditions (298.15 K and 1 atm) were performed using the M06-2X-D3(0) density functional with the ma-def2-TZVP basis set, i.e., at the M06-2X-D3(0) / ma-def2-TZVP level. Electronic energies were then refined with the ma-def2-QZVP basis set. In all computations, the acetonitrile solvent effect was incorporated implicitly using the “Solvation Model based on Density (SMD)” scheme.
[0070] Starting materials
[0071] All substrates were used as received from commercial suppliers, or prepared according to published procedures, respectively, unless otherwise stated. Anilines, nitrates, anddihaloethanes were purchased from Sigma-Aldrich, TCI, Alfa Aesar, BLDPharm, or Chemlmpex.
[0072] Safety statement
[0073] The procedures reported in this work are intended for use only by individuals with proper training in experimental chemistry. All hazardous materials (solid, liquid, or gaseous) should be handled using the standard work procedures described in references such as Chapter 4 of "Prudent Practices in the Laboratory". All chemical waste should be disposed of in accordance with local regulations. For general guidelines for the management of chemical waste, see Chapter 8 of "Prudent Practices in the Laboratory". Reaction set-up, and chemical-specific hazards are highlighted in bold with "Caution:" notes in the procedures reported in these supplementary materials. It is important to note that the absence of a caution note does not imply that no significant hazards are associated with the chemicals involved in that procedure.
[0074]
[0075] Data
[0076] General Procedures for Deaminative
[0077]
[0078] General procedure for deaminative sulfochlorination
[0079] 1 0 equiv. Fe(NO3)3• 9H2O
[0080] 1 0 equiv. Na2S2O3■ 5H2O
[0081] 1 0 equiv. CuCI
[0082] 10 equiv. SO2(3.0 M MeCN)
[0083] 20 equiv. HCI (4.0 M Dioxan)
[0084] NH2MeCN (0.20 M),
[0085] 40 °C, 16 h
[0086]
[0087] Caution: When performing reactions in pressurized vessels (such as closed vials, pressure tubes, and autoclaves), a blast shield must be used to minimize personal damage in case of an accident.
[0088] 0.5 mmol Scale: Under an ambient atmosphere, to a 20-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added the (hetero)aromatic amine (if solid, 0.500 mmol, 1.00 equiv.), Na2S2O3'5H2O (124 mg, 0.500 mmol, 1.00 equiv.) and CuCI (49.5 mg, 0.500 mmol, 1.00 equiv.). Then, acetonitrile (2.5 mL), (hetero)aromatic amine (if liquid, 0.500 mmol, 1.00 equiv.), HCI (4.0 M in 1,4-dioxane, 0.25 mL, 1.0 mmol, 2.0 equiv.), and SO2 (3.0 M in MeCN, 1.7 mL, 5.0 mmol, 10 equiv.) were added, the vial was quickly sealed with a septum cap and the mixture stirred for 5 min at 23 °C. Subsequently, iron(lll) nitrate nonahydrate (202 mg, 0.500 mmol, 1.00 equiv.) was added to the suspension and the vial was quickly resealed with a septum cap. The mixture was then stirred at 40 °C for 18 h. After cooling to 23 °C, the resulting mixture was concentrated by rotary evaporationunder reduced pressure. The residue was diluted with water (5 mL) and extracted with DCM (3 x 5 mL). The organic layers were combined, the solvent was removed under reduced pressure, and the residue dissolved in CDCh (2.0 mL). Dibromomethane was added as internal standard (34.9 pL, 86.9 mg, 0.500 mmol, 1.00 equiv.). The mixture was filtered and a 0.5 mL aliquot of the solution used to record a1H-NMR spectrum. The integration of the CH2Br2 signal (s, 5.0 ppm) was compared to the integration of a signal corresponding to an aromatic proton of the respective sulfonyl chloride (between 6.0-8.0 ppm) to determine the yield.
[0089] General for deaminative sulfochlorination
[0090]
[0091] 1 0 equiv. Fe(NO3)3• 9H2O
[0092] 1 0 equiv. Na2S2O3■ 5H2O
[0093] 1 0 equiv. CuCI
[0094] 10 equiv. SO2(3.0 M MeCN)
[0095] 20 equiv. HCI (4.0 M Dioxan) 40 equiv. pyrrolidine
[0096] DCM, 23 °C, 1 h
[0097] NH2MeCN (0.20 M),
[0098] 40 °C, 16 h
[0099]
[0100] Caution: When performing reactions in pressurized vessels (such as closed vials, pressure tubes, and autoclaves), a blast shield must be used to minimize personal damage in case of an accident.
[0101] 0.5 mmol Scale: Under an ambient atmosphere, to a 20-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added the (hetero)aromatic amine (if solid, 0.500 mmol, 1.00 equiv.), Na2S2O3'5H2O (124 mg, 0.500 mmol, 1.00 equiv.) and CuCI (49.5 mg, 0.500 mmol, 1.00 equiv.). Then, acetonitrile (2.5 mL), (hetero)aromatic amine (if liquid, 0.500 mmol, 1.00 equiv.), HCI (4.0 M in 1,4-dioxane, 0.25 mL, 1.0 mmol, 2.0 equiv.), and SC>2(3.0 M in MeCN, 1.7 mL, 5.0 mmol, 10.0 equiv.) were added, the vial was quickly sealed with a septum cap and the mixture stirred for 5 min at 23 °C. Subsequently, iron(lll) nitrate nonahydrate (202 mg, 0.500 mmol, 1.00 equiv.) was added to the suspension and the vial was quickly resealed with a septum cap. The mixture was then stirred at 40 °C for 18 h. After cooling to 23 °C, the resulting mixture was concentrated by rotary evaporation under reduced pressure. The residue was diluted with water (5 mL) and extracted with DCM (3 x 5 mL). The organic layers were combined in a 20-mL borosilicate vial and a Teflon-coated magnetic stir bar was added, followed by pyrrolidine (165 pL, 142 mg, 2.00 mmol, 4.00 equiv.). The vessel was sealed with a septum cap and the mixture stirred for 1 h at 23 °C. Subsequently water (5 mL) was added, the aqueous phase decanted and further extracted with EtOAc (3 x 5 mL). The combined organic layers were dried over MgSCL, filtered, and the solvent evaporated under reduced pressure. To obtain analytically pure samples of the sulfonamides, the residue was purified by chromatography on silica gel.10 mmol Scale: Under an ambient atmosphere, to a 350-mL Ace pressure tube equipped with a Teflon-coated magnetic stir bar were added the (hetero)aromatic amine (if solid, 10.0 mmol, 1.00 equiv.), Na2S2O3'5H2O (2.48 g, 10.0 mmol, 1.00 equiv.) and CuCI (990 mg, 10.0 mmol, 1.00 equiv.). Then, acetonitrile (50 mL), (hetero)aromatic amine (if liquid, 10.0 mmol, 1.00 equiv.), HCI (4.0 M in 1,4-dioxane, 5.0 mL, 20 mmol, 2.0 equiv.), and SO2 (3.0 M in MeCN, 32 mL, 0.10 mol, 10 equiv.) were added, the vessel was quickly sealed and the mixture stirred for 5 min at 23 °C. Subsequently, iron(lll) nitrate nonahydrate (4.04 g, 10.0 mmol, 1.00 equiv.) was added to the suspension and the pressure tube was quickly resealed. A blast shield was placed in front of the set up and the mixture was then stirred at 40 °C for 18 h. After cooling to 23 °C, the resulting mixture was transferred to a 100 mL round-bottomed flask and concentrated by rotary evaporation under reduced pressure. The residue was diluted with water (50 mL) and extracted with EtOAc (3 x 75 mL). The organic layers were concentrated in a 250 mL round-bottomed flask by rotary evaporation under reduced pressure. DCM (50 mL) was and a Teflon-coated magnetic stir bar were added, followed by pyrrolidine (3.31 mL, 2.84 g, 40.0 mmol, 4.00 equiv.). The pressure tube was sealed and the mixture stirred for 1 h at 23 °C. Subsequently, the mixture was transferred to a 250 mL separatory funnel and water (50 mL) was added, the aqueous phase decanted and further extracted with DCM (3 x 50 mL). The combined organic layers were dried over MgSCL, filtered, and the solvent evaporated by rotary evaporation under reduced pressure. To obtain analytically pure samples of the sulfonamides, the residue was purified by chromatography on silica gel.
[0102] General procedure for deaminative fluorination
[0103] 20 equiv. Fe(NO3)39H2O
[0104] 1 2 equiv. Na2S2O35H2O
[0105] RlTi” J 30 equiv. NaSbF6RI'^T" 1
[0106] Ju n-PrCN : n-pentane (1 : 1 ) (0.40 M), J
[0107]
[0108] 260 °C, 16 h
[0109] 0.5 mmol Scale: Under an ambient atmosphere, to a 4-mL borosilicate vial equipped with a teflon-coated magnetic stir bar were added the (hetero) aromatic amine (if solid, 0.500 mmol, 1.00 equiv.), Na2S2O3'5H2O (149 mg, 0.600 mmol, 1.20 equiv.), NaSbFe (388 mg, 1.50 mmol, 3.00 equiv.) and iron (III) nitrate nonahydrate (404 mg, 1.00 mmol, 2.00 equiv.). Then, butyronitrile (n-PrCN) (0.625 mL), n-pentane (0.625 mL) (0.4 M overall cone.) and (hetero) aromatic amine (if liquid, 0.500 mmol, 1.00 equiv.) were added, the vial was quickly sealed with a septum cap and the reaction mixture stirred at 60 °C for 16 h. After cooling to 23 °C, the resulting mixture was passed through a pad of celite (~2.5 g) by eluting with ethyl acetate (50 ml). Then, the solvent was evaporated by rotary evaporation under reduced pressure. In order to obtain analytically pure samples of fluoroarenes, theresidue was purified by chromatography on silica gel.
[0110] General procedures for deaminative cyanation
[0111] 2 0 equiv. Fe(NO3)39H2O
[0112] 1 2 equiv. Na2SO3
[0113] 2 0 equiv. CuCN
[0114] MeCN (0.40 M),
[0115]
[0116] 70 °C, 12 h CN
[0117] 0.5 mmol Scale: Under an ambient atmosphere, to a 4-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added the (hetero) aromatic amine (if solid, 0.500 mmol, 1.00 equiv.), Na2SOs (75.7 mg, 0.600 mmol, 1.20 equiv.), CuCN (89.6 mg, 1.00 mmol, 2.00 equiv.) and iron (III) nitrate nonahydrate (404 mg, 1.00 mmol, 2.00 equiv.) (Fig. S1A). Then, acetonitrile (MeCN) (1.25 mL, c = 0.40 M), (hetero) aromatic amine (if liquid, 0.500 mmol, 1.00 equiv.) were added. The vessel was sealed with a septum cap (Fig. S1B) and heated at 70°C for 12 h in an aluminum block on a heating plate (Fig. S1C). After cooling to 23 °C, the resulting mixture was passed through a pad of celite by eluting with ethyl acetate (50 mL). Then, the solvent was evaporated by rotary evaporation under reduced pressure. In order to obtain analytically pure samples of benzonitriles, the residue was purified by chromatography on silica gel.
[0118] Reaction set-up for 0.500 mmol scale reactions is as follows:
[0119] A) Weigh all the solids in a 4-mL borosilicate vial equipped with a magnetic stir bar.
[0120] B) Addition of acetonitrile and sealed with a septum cap.
[0121] C) The reaction is heated at 70°C for 12 h in an aluminum block on a heating plate.
[0122]
[0123] with Subsequent Derivatization
[0124] Deaminative sulfochlorination for sulfonyl chloride 4
[0125] 1.0 equiv. Fe(NO3)3■ 9H2O
[0126] 1.0 equiv. Na2S2O3■ 5H2O
[0127] 1.0 equiv. CuCI
[0128] 10 equiv. SO2(3.0 M MeCN)
[0129] 2 0 equiv. HCI (4.0 M Dioxan)
[0130] MeCN (020 M),
[0131] 40 °C, 16 h
[0132]
[0133] 4, 82%
[0134] Under an ambient atmosphere, to a 20-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added reduced Flutamide 3 (123 mg, 0.500 mmol, 1.00 equiv.), Na2S2O3'5H2O (124 mg, 0.500 mmol, 1.00 equiv.) and CuCI (49.5 mg, 0.500 mmol, 1.0 equiv.). Then, acetonitrile (2.5 mL), HCI (4.0 M in 1,4-dioxane, 250 pL, 1.00 mmol, 2.0 equiv.), and SO2 (3.0 M in MeCN, 1.7 mL, 5.0 mmol, 10 equiv.) were added, the vialwas quickly sealed with a septum cap and the mixture stirred for 5 min at 23 °C. Subsequently, iron(lll) nitrate nonahydrate (202 mg, 0.500 mmol, 1.00 equiv.) was added to the suspension and the vial was quickly resealed with a septum cap. The mixture was then stirred at 40 °C for 18 h. After cooling to 23 °C, the resulting mixture was concentrated by rotary evaporation under reduced pressure. The residue was diluted with water (5 mL) and extracted with EtOAc (3 x 5 mL). The organic layers were combined in a 20-mL borosilicate vial and concentrated by rotary evaporation under reduced pressure. The residue was purified by column chromatography on silica with ethyl acetate in pentane (gradient, 0%-50% over 50 column volumes) as eluent, to give the desired sulfonyl chloride 4 as a yellow solid (0.13 g, 0.41 mmol, 82%).
[0135] Rf = 0.61 (EtOAc in cyclohexane = 50%, v / v (UV)).
[0136] HRMS-ESI (m / z) calc’d for C11H10N1O3S1F3CI1 [M-H]’, 328.0028; found, 328.0029; deviation: -0.6 ppm.
[0137] Deaminative sulfoamidation for sulfonamide 5
[0138] 1 0 equiv. Fe(NO3)3■ 9H2O 1 0 equiv. Na2S2O3■ 5H2O 1 0 equiv. CuCI 10 equiv. SO2(3.0 M MeCN) 40 equiv.
[0139] 20 equiv. HCI (4.0 M Dioxan) NH3(1 ,4-dioxane) MeCN (0.20 M), DCM, 23 °C, 40 °C, 16 h 1 h
[0140]
[0141] 5, 46% Under an ambient atmosphere, to a 20-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added reduced Flutamide 3 (123 mg, 0.500 mmol, 1.00 equiv.), Na2S2O3'5H2O (124 mg, 0.500 mmol, 1.00 equiv.) and CuCI (49.5 mg, 0.500 mmol, 1.0 equiv.). Then, acetonitrile (2.5 mL), HCI (4.0 M in 1,4-dioxane, 250 pL, 1.00 mmol, 2.0 equiv.), and SO2 (3.0 M in MeCN, 1.7 mL, 5.0 mmol, 10 equiv.) were added, the vial was quickly sealed with a septum cap and the mixture stirred for 5 min at 23 °C. Subsequently, iron(lll) nitrate nonahydrate (202 mg, 0.500 mmol, 1.00 equiv.) was added to the suspension and the vial was quickly resealed with a septum cap. The mixture was then stirred at 40 °C for 18 h. After cooling to 23 °C, the resulting mixture was concentrated by rotary evaporation under reduced pressure. The residue was diluted with water (5 mL) and extracted with EtOAc (3 x 5 mL). The organic layers were combined in a 20-mL borosilicate vial and concentrated by rotary evaporation under reduced pressure. Then, DCM (5 mL) was added, followed by a Teflon-coated magnetic stir bar and NH3 (0.5 M in 1,4-dioxane, 4.00 mL, 171 mg, 2.00 mmol, 4.00 equiv.). The vessel was sealed with a septum cap and the mixture stirred for 1 h at 23 °C. Subsequently, HCI solution (10% aqueous, 5 mL) was added, and the mixture extracted with EtOAc (3 x 5 mL). The combinedorganic layers were dried over MgSCU, filtered, and the solvent evaporated under reduced pressure. The residue was purified by column chromatography on silica with ethyl acetate in pentane (gradient, 0%-100% over 50 column volumes) as eluent, to give the desired primary sulfonamide 5 as a white solid (70 mg, 0.23 mmol, 46%).
[0142] Rf = 0.45 (MeOH in DCM = 5%, v / v (UV)).
[0143] HRMS-EI (m / z) calc’d for C11H13N2O3S1F3 [M]+, 310.0594; found, 310.0594; deviation: -0.3 ppm.
[0144] Deaminative sulfoamidation for sulfonamide 6
[0145] 1 0 equiv. Fe(NO3)3■ 9H2O
[0146] 1 0 equiv. Na2S2O3■ 5H2O
[0147] 1 0 equiv. CuCI
[0148] 10 equiv. SO2(3.0 M MeCN)
[0149] 20 equiv. HCI (4.0 M Dioxan)
[0150] MeCN (0.20 M),
[0151] 40 °C, 16 h
[0152] 3
[0153] 40 equiv.
[0154] DCM, 23 °C,
[0155] 1 h
[0156]
[0157] 6, 70%
[0158] Under an ambient atmosphere, to a 20-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added reduced Flutamide 3 (123 mg, 0.500 mmol, 1.00 equiv.), Na2S2O3'5H2O (124 mg, 0.500 mmol, 1.00 equiv.) and CuCI (49.5 mg, 0.500 mmol, 1.0 equiv.). Then, acetonitrile (2.5 mL), HCI (4.0 M in 1,4-dioxane, 250 pL, 1.00 mmol, 2.0 equiv.), and SO2 (3.0 M in MeCN, 1.7 mL, 5.0 mmol, 10 equiv.) were added, the vial was quickly sealed with a septum cap and the mixture stirred for 5 min at 23 °C. Subsequently, iron(lll) nitrate nonahydrate (202 mg, 0.500 mmol, 1.00 equiv.) was added to the suspension and the vial was quickly resealed with a septum cap. The mixture was then stirred at 40 °C for 18 h. After cooling to 23 °C, the resulting mixture was concentrated by rotary evaporation under reduced pressure. The residue was diluted with water (5 mL) and extracted with EtOAc (3 x 5 mL). The organic layers were combined in a 20-mL borosilicate vial and concentrated by rotary evaporation under reduced pressure. Then, DCM (5 mL) was added, followed by a Teflon-coated magnetic stir bar and N- acetylethylenediamine (0.213 mL, 227 mg, 2.00 mmol, 4.00 equiv.). The vessel was sealed with a septum cap and the mixture stirred for 1 h at 23 °C. Subsequently, water (5 mL) was added, and the mixture extracted with EtOAc (3 x 5 mL). The combined organic layers were dried over MgSO4, filtered, and the solvent evaporated under reduced pressure. The residue was purified by column chromatography on silica with ethyl acetate in pentane(gradient, 0%-100% over 30 column volumes, followed by 100% over 20 column volumes) as eluent, to give the desired secondary sulfonamide 6 as a white solid (139 mg, 0.35 mmol, 70%).
[0159] Rf = 0.53 (MeOH in DCM = 10%, v / v (UV)).
[0160] HRMS-ESI (m / z) calc’d for Cisl^oNsC SiFsNai [M+Na]+, 418.1019; found, 418.1015; deviation: +0.8 ppm.
[0161] Deaminative sulfoamidation for sulfonamide 7
[0162] 1.0 equiv. Fe(NO3)3■ 9H2O
[0163] 1.0 equiv. Na2S2O3■ 5H2O
[0164] 1.0 equiv. CuCI
[0165] 10 equiv. SO2(30 M MeCN)
[0166] 20 equiv. HCI (40 M Dioxan)
[0167] MeCN (0.20 M),
[0168] 40 °C, 16 h
[0169] 3
[0170] 1 0 equiv. K2CO3
[0171] DCM, 23 °C,
[0172]
[0173] 1 h
[0174] Under an ambient atmosphere, to a 20-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added reduced Flutamide 3 (123 mg, 0.500 mmol, 1.00 equiv.), Na2S2O3'5H2O (124 mg, 0.500 mmol, 1.00 equiv.) and CuCI (49.5 mg, 0.500 mmol, 1.0 equiv.). Then, acetonitrile (2.5 mL), HCI (4.0 M in 1,4-dioxane, 250 pL, 1.00 mmol, 2.0 equiv.), and SO2 (3.0 M in MeCN, 1.7 mL, 5.0 mmol, 10 equiv.) were added, the vial was quickly sealed with a septum cap and the mixture stirred for 5 min at 23 °C. Subsequently, iron(lll) nitrate nonahydrate (202 mg, 0.500 mmol, 1.00 equiv.) was added to the suspension and the vial was quickly resealed with a septum cap. The mixture was then stirred at 40 °C for 18 h. After cooling to 23 °C, the resulting mixture was concentrated by rotary evaporation under reduced pressure. The residue was diluted with water (5 mL) and extracted with EtOAc (3 x 5 mL). The organic layers were combined in a 20-mL borosilicate vial and concentrated by rotary evaporation under reduced pressure. Then, DCM (5 mL) was added, followed by a Teflon-coated magnetic stir bar, K2CO3 (69.1 mg, 0.50 mmol, 1.00 equiv), and Troxipid S1 (147 mg, 0.50 mmol, 1.00 equiv.). The vessel was sealed with a septum cap and the mixture stirred for 1 h at 23 °C. Subsequently, water (5 mL) was added, and the mixture extracted with EtOAc (3 x 5 mL). The combined organic layers were dried over MgSO4, filtered, and the solvent evaporated under reduced pressure. The residue was purified by column chromatography on silica with ethyl acetate in pentane(gradient, 0%-100% over 50 column volumes) as eluent, to give the desired tertiary sulfonamide 7 as a white solid (129 mg, 0.22 mmol, 44%).
[0175] Rf = 0.55 (MeOH in DCM = 10%, v / v (UV)).
[0176] HRMS-ESI (m / z) calc’d for C26H32N3O7SiF3Nai [M+Na]+, 610.1805; found, 610.1808; deviation: -0.5 ppm.
[0177] Deaminative sulfofluorination for sulfonyl fluoride 8
[0178] 1 0 equiv. Fe(NO3)3■ 9H2O 1 0 equiv. Na2S2O3■ 5H2O 1 0 equiv. CuCI 10 equiv. SO2(3.0 M MeCN) 20 equiv. 7e H20 equiv. HCI (4.0 M Dioxan) _ CsF Me >| MeCN (0.20 M), MeCN, 85 °C,040 °C, 16 h 2 h j?'F
[0179] O
[0180]
[0181] 8, 57% Under an ambient atmosphere, to a 20-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added reduced Flutamide 3 (123 mg, 0.500 mmol, 1.00 equiv.), Na2S2O3'5H2O (124 mg, 0.500 mmol, 1.00 equiv.) and CuCI (49.5 mg, 0.500 mmol, 1.0 equiv.). Then, acetonitrile (2.5 mL), HCI (4.0 M in 1,4-dioxane, 250 pL, 1.00 mmol, 2.0 equiv.), and SO2(3.0 M in MeCN, 1.7 mL, 5.0 mmol, 10 equiv.) were added, the vial was quickly sealed with a septum cap and the mixture stirred for 5 min at 23 °C. Subsequently, iron(lll) nitrate nonahydrate (202 mg, 0.500 mmol, 1.00 equiv.) was added to the suspension and the vial was quickly resealed with a septum cap. The mixture was then stirred at 40 °C for 18 h. After cooling to 23 °C, the resulting mixture was concentrated by rotary evaporation under reduced pressure. The residue was diluted with water (5 mL) and extracted with EtOAc (3 x 5 mL). The organic layers were combined in a 20-mL borosilicate vial and concentrated by rotary evaporation under reduced pressure. Then, MeCN (5 mL) was added, followed by a Teflon-coated magnetic stir bar and CsF (152 mg, 1.00 mmol, 2.00 equiv.). The vessel was sealed with a septum cap and the mixture stirred for 2 h at 85 °C. Subsequently, sat. aq. NaHCOs solution (5 mL) was added, and the mixture extracted with EtOAc (3 x 5 mL). The combined organic layers were dried over MgSO4, filtered, and the solvent evaporated under reduced pressure. The residue was purified by column chromatography on silica with ethyl acetate in pentane (gradient, 0%-30% over 50 column volumes) as eluent, to give the desired sulfonyl fluoride 8 as a faint yellow solid (89 mg, 0.28 mmol, 57%).
[0182] Rf = 0.60 (EtOAc in cyclohexane = 50%, v / v (UV)).
[0183] HRMS-EI (m / z) calc’d for C11H11N1O3S1F4 [M]+, 313.0390; found, 313.0390; deviation: +0.1 ppm.Deaminative sulfonic acid synthesis for sulfonic acid 9
[0184] 1 0 equiv. Fe(NO3)3• 9H2O 1 0 equiv. Na2S2O35H2O 1 0 equiv. CuCI 10 equiv. SO2(3.0 M MeCN) 10 equiv. H2O 20 equiv. HCI (4.0 M Dioxan) 20 equiv. K2CO3MeCN (020 M), MeCN, reflux, 40 °C, 16 h 18 h
[0185]
[0186] 9, 55% Under an ambient atmosphere, to a 20-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added reduced Flutamide 3 (123 mg, 0.500 mmol, 1.00 equiv.), Na2S2O3'5H2O (124 mg, 0.500 mmol, 1.00 equiv.) and CuCI (49.5 mg, 0.500 mmol, 1.0 equiv.). Then, acetonitrile (2.5 mL), HCI (4.0 M in 1,4-dioxane, 250 pL, 1.00 mmol, 2.0 equiv.), and SO2 (3.0 M in MeCN, 1.7 mL, 5.0 mmol, 10 equiv.) were added, the vial was quickly sealed with a septum cap and the mixture stirred for 5 min at 23 °C. Subsequently, iron(lll) nitrate nonahydrate (202 mg, 0.500 mmol, 1.00 equiv.) was added to the suspension and the vial was quickly resealed with a septum cap. The mixture was then stirred at 40 °C for 18 h. After cooling to 23 °C, the resulting mixture was concentrated by rotary evaporation under reduced pressure. The residue was diluted with water (5 mL) and extracted with EtOAc (3 x 5 mL). The organic layers were combined in a 20-mL borosilicate vial and concentrated by rotary evaporation under reduced pressure. Then, MeCN (5 mL) was added, followed by a Teflon-coated magnetic stir bar, K2CO3 (138 mg, 1.00 mmol, 2.00 equiv.), and deionized H2O (0.90 mL, 90.1 mg, 5.00 mmol, 10.0 equiv.). The vessel was sealed with a septum cap and the mixture stirred for 18 h at 85 °C. Subsequently, the solvent was evaporated and the residue purified by reversed phase column chromatography on C18with MeOH in H2O + 0.1% formic acid (gradient, 0%-100% over 50 column volumes) as eluent, to give the desired sulfonic acid 9 as a white solid (86 mg, 0.28 mmol, 55%).
[0187] Rf = 0.29 (MeOH in DCM = 20%, v / v (UV)).
[0188] HRMS-EI (m / z) calc’d for C11 H11 N1O4S1F3 [M]+, 310.0366; found, 310.0369; deviation: -0.9 ppm.Aniline Scope for Deaminative Sulfochlorination (isolation as sulfonamides) 4-(Pyrrolidin-1-ylsulfonyl)benzonitrile (10)
[0189] 1 0 equiv. Fe(NO3)39H2O
[0190] 1 0 equiv. Na2S2O3• 5H2O
[0191] 1 0 equiv. CuCI
[0192] 10 equiv. SO2(3.0 M MeCN)
[0193] 20 equiv. HCI (4.0 M Dioxan) 40 equiv. pyrrolidine
[0194] MeCN (0.20 M), DCM, 23 °C, 1 h
[0195] 40 °C, 16 h
[0196]
[0197] 1a 10, 73%
[0198] Under an ambient atmosphere, to a 20-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added 4-aminobenzonitrile (59.1 mg, 0.500 mmol, I.OO equiv.), Na2S2O3'5H2O (124 mg, 0.500 mmol, I.OO equiv.) and CuCI (49.5 mg, 0.500 mmol, I.O equiv.). Then, acetonitrile (2.5 mL), HCI (4.0 M in 1,4-dioxane, 250 pL, 1.00 mmol, 2.0 equiv.), and SO2 (3.0 M in MeCN, 1.7 mL, 5.0 mmol, 10 equiv.) were added, the vial was quickly sealed with a septum cap and the mixture stirred for 5 min at 23 °C. Subsequently, iron(lll) nitrate nonahydrate (202 mg, 0.500 mmol, 1.00 equiv.) was added to the suspension and the vial was quickly resealed with a septum cap. The mixture was then stirred at 40 °C for 18 h. After cooling to 23 °C, the resulting mixture was concentrated by rotary evaporation under reduced pressure. The residue was diluted with water (5 mL) and extracted with DCM (3 x 5 mL). The organic layers were combined in a 20-mL borosilicate vial and a Teflon-coated magnetic stir bar was added, followed by pyrrolidine (165 pL, 142 mg, 2.00 mmol, 4.00 equiv.). The vessel was sealed with a septum cap and the mixture stirred for 1 h at 23 °C. Subsequently water (5 mL) was added, the aqueous phase decanted and further extracted with DCM (3 x 5 mL). The combined organic layers were dried over MgSCL, filtered, and the solvent evaporated under reduced pressure. The residue was purified by column chromatography on silica with ethyl acetate in cyclohexane (gradient, 0%-50% over 30 column volumes) as eluent, to give the desired sulfonamide 10 as a colorless solid (86 mg, 0.36 mmol, 73%).
[0199] Rf = 0.21 (EtOAc in cyclohexane = 20%, v / v (UV)).
[0200] HRMS-EI (m / z) calc’d for C11H12N2O2S1 [M]+, 236.0614; found, 236.0614; deviation: +0.1 ppm.1-((4-Phenoxyphenyl)sulfonyl)pyrrolidine (11)
[0201] 1 0 equiv Fe(NO3)39H2O
[0202] 1 0 equiv Na2S2O3■ 5H2O
[0203] 1 0 equiv CuCI
[0204] 10 equiv SO2(30 M MeCN)
[0205] 20 equiv HCI (40 M Dioxan) 4.0 equiv pyrrolidine
[0206] MeCN (020 M), DCM, 23 °C, 1 h
[0207] 40 °C, 16 h
[0208]
[0209] 11a 11, 63%
[0210] Under an ambient atmosphere, to a 20-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added 4-phenoxyaniline (92.3 mg, 0.500 mmol, 1.00 equiv.), Na2S2O3'5H2O (124 mg, 0.500 mmol, 1.00 equiv.) and CuCI (49.5 mg, 0.500 mmol, 1.0 equiv.). Then, acetonitrile (2.5 mL), HCI (4.0 M in 1,4-dioxane, 250 pL, 1.00 mmol, 2.0 equiv.), and SO2 (3.0 M in MeCN, 1.7 mL, 5.0 mmol, 10 equiv.) were added, the vial was quickly sealed with a septum cap and the mixture stirred for 5 min at 23 °C. Subsequently, iron(lll) nitrate nonahydrate (202 mg, 0.500 mmol, 1.00 equiv.) was added to the suspension and the vial was quickly resealed with a septum cap. The mixture was then stirred at 40 °C for 18 h. After cooling to 23 °C, the resulting mixture was concentrated by rotary evaporation under reduced pressure. The residue was diluted with water (5 mL) and extracted with DCM (3 x 5 mL). The organic layers were combined in a 20-mL borosilicate vial and a Teflon-coated magnetic stir bar was added, followed by pyrrolidine (165 pL, 142 mg, 2.00 mmol, 4.00 equiv.). The vessel was sealed with a septum cap and the mixture stirred for 1 h at 23 °C. Subsequently water (5 mL) was added, the aqueous phase decanted and further extracted with DCM (3 x 5 mL). The combined organic layers were dried over MgSCL, filtered, and the solvent evaporated under reduced pressure. The residue was purified by column chromatography on silica with ethyl acetate in cyclohexane (gradient, 0%-50% over 30 column volumes) as eluent, to give the desired sulfonamide 11 as a colorless solid (95 mg, 0.31 mmol, 63%).
[0211] Rf = 0.42 (EtOAc in cylohexane = 20%, v / v (UV)).
[0212] HRMS-EI (m / z) calc’d for C16H17N1O3S1 [M]+, 303.0924; found, 303.0928; deviation: -1.3 ppm.1-((4-Methoxyphenyl)sulfonyl)pyrrolidine (12)
[0213] 1 0 equiv Fe(NO3)39H2O
[0214] 1 0 equiv Na2S2O3■ 5H2O
[0215] OMe
[0216] 10 equiv SO2(3.0 M MeCN) OMe
[0217] OMe 2 0 equiv HCI (4 0 M Dioxan) 4 0 equiv pyrrolidine
[0218] MeCN (0 20 M), DCM, 23 °C, 1 h
[0219] 40 °C, 16 h
[0220] O'^'O
[0221] NH2°'t'°
[0222]
[0223] 12a 12, 46%
[0224] Under an ambient atmosphere, to a 4-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added 4-methoxyaniline (12.3 mg, 0.100 mmol, 1.00 equiv.), Na2S2O3'5H2O (24.8 mg, 0.100 mmol, 1.00 equiv.) and CuCI (9.90 mg, 0.100 mmol, 1.0 equiv.). Then, acetonitrile (0.5 mL), HCI (4.0 M in 1,4-dioxane, 50 pL, 0.10 mmol, 2.0 equiv.), and SO2 (3.0M in MeCN, 0.323 mL, 1.00 mmol, 10.0 equiv.) were added, the vial was quickly sealed with a septum cap and the mixture stirred for 5 min at 23 °C. Subsequently, iron(lll) nitrate nonahydrate (40.4 mg, 0.100 mmol, 1.00 equiv.) was added to the suspension and the vial was quickly resealed with a septum cap. The mixture was then stirred at 40 °C for 18 h. After cooling to 23 °C, the resulting mixture was concentrated by rotary evaporation under reduced pressure. The residue was diluted with water (2 mL) and extracted with DCM (3 x 2 mL). The organic layers were combined in a 4-mL borosilicate vial and a Teflon-coated magnetic stir bar was added, followed by pyrrolidine (33.1 pL, 28.4 mg, 0.400 mmol, 4.00 equiv.). The vessel was sealed with a septum cap and the mixture stirred for 1 h at 23 °C. Subsequently water (5 mL) was added, the aqueous phase decanted and further extracted with DCM (3 x 5 mL). The combined organic layers were dried over MgSCL, filtered, and the solvent evaporated under reduced pressure. The residue was purified by column chromatography on silica with ethyl acetate in cyclohexane (gradient, 0%-50% over 30 column volumes) as eluent, to give the desired sulfonamide 12 as a colorless solid (11.2 mg, 0.46 mmol, 46%).
[0225] Rf = 0.22 (EtOAc in pentane = 20%, v / v (UV)).
[0226] HRMS-EI (m / z) calc’d for C11H15N1O3S1 [M]+, 241.0767; found, 241.0765; deviation: -0.77 ppm.
[0227] 2-Chloro-3-(pyrrolidin-1-ylsulfonyl)pyridine (13)
[0228] 1 0 equiv. Fe(NO3)3■ 9H2O
[0229] 1 0 equiv. Na2S2O3■ 5H2O
[0230] 1 0 equiv. CuCI
[0231] 10 equiv. SO2(3 0 M MeCN)
[0232] 2 0 equiv. HCI (4 0 M Dioxan) 4 0 equiv. pyrrolidine
[0233] MeCN (0 20 M), DCM, 23 °C, 1 h
[0234] 40 °C, 16 h
[0235]
[0236] 13a 13, 55%Under an ambient atmosphere, to a 20-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added 3-amino-2-chloropyridine (64.3 mg, 0.500 mmol, 1.00 equiv.), Na2S2O3'5H2O (124 mg, 0.500 mmol, 1.00 equiv.) and CuCI (49.5 mg, 0.500 mmol, 1.0 equiv.). Then, acetonitrile (2.5 mL), HCI (4.0 M in 1,4-dioxane, 250 pL, 1.00 mmol, 2.0 equiv.), and SO2 (3.0 M in MeCN, 1.7 mL, 5.0 mmol, 10 equiv.) were added, the vial was quickly sealed with a septum cap and the mixture stirred for 5 min at 23 °C. Subsequently, iron(lll) nitrate nonahydrate (202 mg, 0.500 mmol, 1.00 equiv.) was added to the suspension and the vial was quickly resealed with a septum cap. The mixture was then stirred at 40 °C for 18 h. After cooling to 23 °C, the resulting mixture was concentrated by rotary evaporation under reduced pressure. The residue was diluted with water (5 mL) and extracted with DCM (3 x 5 mL). The organic layers were combined in a 20-mL borosilicate vial and a Teflon-coated magnetic stir bar was added, followed by pyrrolidine (165 pL, 142 mg, 2.00 mmol, 4.00 equiv.). The vessel was sealed with a septum cap and the mixture stirred for 1 h at 23 °C. Subsequently water (5 mL) was added, the aqueous phase decanted and further extracted with DCM (3 x 5 mL). The combined organic layers were dried over MgSCL, filtered, and the solvent evaporated under reduced pressure. The residue was purified by column chromatography on silica with ethyl acetate in pentane (15%, v / v) as eluent, to give the desired sulfonamide 13 as a colorless oil (68 mg, 0.28 mmol, 55%).
[0237] Rf = 0.25 (EtOAc in pentane = 40%, v / v (UV)).
[0238] HRMS-ESI (m / z) calc’d for C9HiiN2O2SiCliNai [M+Na]+, 269.0122; found, 269.0122; deviation: +0.2 ppm.
[0239] 1-((4'-Chloro-[1,1'-biphenyl]-2-yl)sulfonyl)pyrrolidine (14)
[0240] 1.0 equiv. Fe(NO3)3• 9H2O
[0241] 1.0 equiv. Na2S2O3• 5H2O
[0242] 1.0 equiv. CuCI
[0243] 10 equiv. SO2(3.0 M MeCN)
[0244] 20 equiv. HCI (4.0 M Dioxan) 40 equiv. pyrrolidine
[0245] MeCN (020 M), DCM, 23 °C, 1 h
[0246] 40 °C, 16 h
[0247]
[0248] 14a 14, 83%
[0249] Under an ambient atmosphere, to a 20-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added 4-chloro-(1-biphenyl)-2-amine (102 mg, 0.500 mmol, 1.00 equiv.), Na2S2C>3-5H2O (124 mg, 0.500 mmol, 1.00 equiv.) and CuCI (49.5 mg, 0.500 mmol, 1.0 equiv.). Then, acetonitrile (2.5 mL), HCI (4.0 M in 1,4-dioxane, 250 pL, 1.00 mmol, 2.0 equiv.), and SC>2(3.0 M in MeCN, 1.7 mL, 5.0 mmol, 10 equiv.) were added, the vial was quickly sealed with a septum cap and the mixture stirred for 5 min at 23 °C.Subsequently, iron(lll) nitrate nonahydrate (202 mg, 0.500 mmol, 1.00 equiv.) was added to the suspension and the vial was quickly resealed with a septum cap. The mixture was then stirred at 40 °C for 18 h. After cooling to 23 °C, the resulting mixture was concentrated by rotary evaporation under reduced pressure. The residue was diluted with water (5 mL) and extracted with DCM (3 x 5 mL). The organic layers were combined in a 20-mL borosilicate vial and a Teflon-coated magnetic stir bar was added, followed by pyrrolidine (165 pL, 142 mg, 2.00 mmol, 4.00 equiv.). The vessel was sealed with a septum cap and the mixture stirred for 1 h at 23 °C. Subsequently water (5 mL) was added, the aqueous phase decanted and further extracted with DCM (3 x 5 mL). The combined organic layers were dried over MgSCL, filtered, and the solvent evaporated under reduced pressure. The residue was purified by column chromatography on silica with ethyl acetate in cyclohexane (gradient, 0%-50% over 30 column volumes) as eluent, to give the desired sulfonamide 14 as a colorless solid (0.13 mg, 0.42 mmol, 83%).
[0250] Rf = 0.49 (EtOAc in cyclohexane = 20%, v / v (UV)).
[0251] HRMS-EI (m / z) calc’d forCi6Hi6N2O2SiCli [M]+, 321.0585; found, 321.0588; deviation: -1.2 ppm.
[0252] 3-(Pyrrolidin-1-ylsulfonyl)-5-(trifluoromethyl)benzoic acid (15)
[0253] 1 0 equiv. Fe(NO3)39H2O 1 0 equiv. Na2S2O35H2O 1 0 equiv. CuCI 10 equiv. SO2(3.0 M MeCN) 20 equiv. HCI (4.0 M Dioxan) MeCN (020 M), 40 °C, 16 h
[0254]
[0255] 15, 69% Under an ambient atmosphere, to a 20-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added 3-amino-5-(trifluormethyl)-benzoicacid (103 mg, 0.500 mmol, 1.00 equiv.), Na2S2O3'5H2O (124 mg, 0.500 mmol, 1.00 equiv.) and CuCI (49.5 mg, 0.500 mmol, 1.0 equiv.). Then, acetonitrile (2.5 mL), HCI (4.0 M in 1,4-dioxane, 250 pL, 1.00 mmol, 2.0 equiv.), and SO2(3.0 M in MeCN, 1.7 mL, 5.0 mmol, 10 equiv.) were added, the vial was quickly sealed with a septum cap and the mixture stirred for 5 min at 23 °C. Subsequently, iron(lll) nitrate nonahydrate (202 mg, 0.500 mmol, 1.00 equiv.) was added to the suspension and the vial was quickly resealed with a septum cap. The mixture was then stirred at 40 °C for 18 h. After cooling to 23 °C, the resulting mixture was concentrated by rotary evaporation under reduced pressure. The residue was diluted with water (5 mL) and extracted with DCM (3 x 5 mL). The organic layers were combined in a 20-mL borosilicate vial and a Teflon-coated magnetic stir bar was added, followed by pyrrolidine(165 pL, 142 mg, 2.00 mmol, 4.00 equiv.). The vessel was sealed with a septum cap and the mixture stirred for 1 h at 23 °C. Subsequently water (5 mL) was added, the aqueous phase decanted and further extracted with DCM (3 x 5 mL). The combined organic layers were dried over MgSCL, filtered, and the solvent evaporated under reduced pressure. The residue was purified by column chromatography on silica with ethyl acetate in pentane (38% + 2% AcOH) as eluent, to give the desired sulfonamide 15 as an off-white solid (0.11 mg, 0.35 mmol, 69%).
[0256] Rf = 0.74 (EtOAc in pentane = 28% + 2% AcOH, v / v (UV)).
[0257] HRMS-ESI (m / z) calc’d for Ci2Hi2NiO4SiF3Nai [M+Na]+, 346.0331; found, 346.0332; deviation: -0.1 ppm.
[0258] 4-(Pyrrolidin-1-ylsulfonyl)nitrobenzene (16)
[0259] 1 0 equiv. Fe(NO3)3■ 9H2O
[0260] 1 0 equiv. Na2S2O3■ 5H2O
[0261] 1 0 equiv. CuCI
[0262] 10 equiv. SO2(3.0 M MeCN)
[0263] 20 equiv. HCI (4.0 M Dioxan) 40 equiv. pyrrolidine
[0264] MeCN (0.20 M), DCM, 23 °C, 1 h
[0265] 40 °C, 16 h
[0266]
[0267] 16a
[0268] Under an ambient atmosphere, to a 20-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added 4-nitroaniline (69.1 mg, 0.500 mmol, 1.00 equiv.), Na2S2O3'5H2O (124 mg, 0.500 mmol, 1.00 equiv.) and CuCI (49.5 mg, 0.500 mmol, 1.0 equiv.). Then, acetonitrile (2.5 mL), HCI (4.0 M in 1,4-dioxane, 250 pL, 1.00 mmol, 2.0 equiv.), and SO2 (3.0 M in MeCN, 1.7 mL, 5.0 mmol, 10 equiv.) were added, the vial was quickly sealed with a septum cap and the mixture stirred for 5 min at 23 °C. Subsequently, iron(lll) nitrate nonahydrate (202 mg, 0.500 mmol, 1.00 equiv.) was added to the suspension and the vial was quickly resealed with a septum cap. The mixture was then stirred at 40 °C for 18 h. After cooling to 23 °C, the resulting mixture was concentrated by rotary evaporation under reduced pressure. The residue was diluted with water (5 mL) and extracted with DCM (3 x 5 mL). The organic layers were combined in a 20-mL borosilicate vial and a Teflon-coated magnetic stir bar was added, followed by pyrrolidine (165 pL, 142 mg, 2.00 mmol, 4.00 equiv.). The vessel was sealed with a septum cap and the mixture stirred for 1 h at 23 °C. Subsequently water (5 mL) was added, the aqueous phase decanted and further extracted with DCM (3 x 5 mL). The combined organic layers were dried over MgSCL, filtered, and the solvent evaporated under reduced pressure. The residue was purified by column chromatography on silica with ethyl acetate in pentane(12%, v / v) as eluent, to give the desired sulfonamide 16 as a yellow solid (81 mg, 0.32 mmol, 63%).
[0269] Rf = 0.37 (EtOAc in pentane = 12%, v / v (UV)).
[0270] HRMS-EI (m / z) calc’d for C10H12N2O4S1 [M]+, 256.0512; found, 256.0512; deviation: +0.3 ppm.
[0271] 1-((2-Chloro-4-iodophenyl)sulfonyl)pyrrolidine (17)
[0272] 1 0 equiv. Fe(NO3)3■ 9H2O
[0273] 1 0 equiv. Na2S2O3■ 5H2O
[0274] 1 0 equiv. CuCI I
[0275] 10 equiv. SO2(3.0 M MeCN)
[0276] 20 equiv. HCI (4.0 M Dioxan) 40 equiv. pyrrolidine
[0277] MeCN (0.20 M), DCM, 23 °C, 1 h
[0278] 40 °C, 16 h
[0279]
[0280] 17a 17, 70%
[0281] Under an ambient atmosphere, to a 20-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added 2-chloro-4-iodaniline (127 mg, 0.500 mmol, 1.00 equiv.), Na2S2O3'5H2O (124 mg, 0.500 mmol, 1.00 equiv.) and CuCI (49.5 mg, 0.500 mmol, 1.0 equiv.). Then, acetonitrile (2.5 mL), HCI (4.0 M in 1,4-dioxane, 250 pL, 1.00 mmol, 2.0 equiv.), and SO2 (3.0 M in MeCN, 1.7 mL, 5.0 mmol, 10 equiv.) were added, the vial was quickly sealed with a septum cap and the mixture stirred for 5 min at 23 °C. Subsequently, iron(lll) nitrate nonahydrate (202 mg, 0.500 mmol, 1.00 equiv.) was added to the suspension and the vial was quickly resealed with a septum cap. The mixture was then stirred at 40 °C for 18 h. After cooling to 23 °C, the resulting mixture was concentrated by rotary evaporation under reduced pressure. The residue was diluted with water (5 mL) and extracted with DCM (3 x 5 mL). The organic layers were combined in a 20-mL borosilicate vial and a Teflon-coated magnetic stir bar was added, followed by pyrrolidine (165 pL, 142 mg, 2.00 mmol, 4.00 equiv.). The vessel was sealed with a septum cap and the mixture stirred for 1 h at 23 °C. Subsequently water (5 mL) was added, the aqueous phase decanted and further extracted with DCM (3 x 5 mL). The combined organic layers were dried over MgSCL, filtered, and the solvent evaporated under reduced pressure. The residue was purified by column chromatography on silica with ethyl acetate in cyclohexane (gradient, 0%-50% over 30 column volumes) as eluent, to give the desired sulfonamide 17 as a colorless solid (0.130 g, 0.35 mmol, 70%).
[0282] Rf = 0.52 (EtOAc in cyclohexane = 20%, v / v (UV)).
[0283] HRMS-EI (m / z) calc’d for C10H11 N1O2S1CI1I1 [M]+, 370.9238; found, 370.9242; deviation: -1.0 ppm.Phenyl(4-(pyrrolidin-1-ylsulfonyl)phenyl)methanone (18)
[0284] 1 0 equiv. Fe(NO3)3■ 9H2O
[0285] 1 0 equiv. Na2S2O35H2O
[0286] 1 0 equiv. CuCI
[0287] 10 equiv. SO2(3.0 M MeCN)
[0288] 20 equiv. HCI (4.0 M Dioxan)
[0289] MeCN (020 M),
[0290] 40 °C, 16 h
[0291]
[0292] 18a 18, 76%
[0293] 0.5 mmol Scale: Under an ambient atmosphere, to a 20-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added 4-aminobenzophenone (98.6 mg, 0.500 mmol, I.OO equiv.), Na2S2O3'5H2O (124 mg, 0.500 mmol, I.OO equiv.) and CuCI (49.5 mg, 0.500 mmol, 1.0 equiv.). Then, acetonitrile (2.5 mL), HCI (4.0 M in 1,4-dioxane, 250 pL, 1.00 mmol, 2.0 equiv.), and SC>2(3.0 M in MeCN, 1.7 mL, 5.0 mmol, 10 equiv.) were added, the vial was quickly sealed with a septum cap and the mixture stirred for 5 min at 23 °C. Subsequently, iron(lll) nitrate nonahydrate (202 mg, 0.500 mmol, I.OO equiv.) was added to the suspension and the vial was quickly resealed with a septum cap. The mixture was then stirred at 40 °C for 18 h. After cooling to 23 °C, the resulting mixture was concentrated by rotary evaporation under reduced pressure. The residue was diluted with water (5 mL) and extracted with DCM (3 x 5 mL). The organic layers were combined in a 20-mL borosilicate vial and a Teflon- coated magnetic stir bar was added, followed by pyrrolidine (165 pL, 142 mg, 2.00 mmol, 4.00 equiv.). The vessel was sealed with a septum cap and the mixture stirred for 1 h at 23 °C. Subsequently water (5 mL) was added, the aqueous phase decanted and further extracted with DCM (3 x 5 mL). The combined organic layers were dried over MgSC>4, filtered, and the solvent evaporated under reduced pressure. The residue was purified by column chromatography on silica with ethyl acetate in cyclohexane (gradient, 0%-50% over 30 column volumes) as eluent, to give the desired sulfonamide 18 as a colorless solid (0.12 g, 0.38 mmol, 76%).
[0294] 10 mmol Scale: Under an ambient atmosphere, to a 350-mL Ace pressure tube equipped with a Teflon-coated magnetic stir bar were added the 4-aminobenzophenone (1.97 g, 10.0 mmol, I.OO equiv.), Na2S2O3'5H2O (2.48 g, 10.0 mmol, I.OO equiv.) and CuCI (990 mg, 10.0 mmol, I.OO equiv.). Then, acetonitrile (50 mL), HCI (4.0 M in 1,4-dioxane, 5.0 mL, 20 mmol, 2.0 equiv.), and SO2 (3.00 M in MeCN, 32.3 mL, 100 mmol, 10.0 equiv.) were added, the vessel was quickly sealed and the mixture stirred for 5 min at 23 °C. Subsequently, iron(lll) nitrate nonahydrate (4.04 g, 10.0 mmol, 1.00 equiv.) was added to the suspension and the pressure tube was quickly resealed. A blast shield was placed in front of the set up and the mixture was then stirred at 40 °C for 18 h. After cooling to 23 °C, the resulting mixture was transferred to a 100 mL round-bottomed flask and concentratedby rotary evaporation under reduced pressure. The residue was diluted with water (50 mL) and extracted with EtOAc (3 x 75 mL). The organic layers were concentrated in a 250 mL round- bottomed flask by rotary evaporation under reduced pressure. DCM (50 mL) and a Teflon-coated magnetic stir bar were added, followed by pyrrolidine (3.31 mL, 2.84 g, 40.0 mmol, 4.00 equiv.). The pressure tube was sealed and the mixture stirred for 1 h at 23 °C. Subsequently, the mixture was transferred to a 250 mL separatory funnel and water (50 mL) was added, the aqueous phase decanted and further extracted with DCM (3 x 50 mL). The combined organic layers were dried over MgSCL, filtered, and the solvent evaporated by rotary evaporation under reduced pressure. The residue was purified by column chromatography on silica with ethyl acetate in pentane (gradient, 0% for 10 column volumes, then 0%-50% over 50 column volumes) as eluent, to give the desired sulfonamide 18 as a faint red solid (1.85 g, 5.87 mmol, 59%).
[0295] 10 mmol Scale and catalytic CuCI: Under an ambient atmosphere, to a 350-mL Ace pressure tube equipped with a Teflon-coated magnetic stir bar were added the 4-aminobenzophenone (1.97 g, 10.0 mmol, 1.00 equiv.), Na2S2C>3-5H2O (2.48 g, 10.0 mmol, 1.00 equiv.) and CuCI (197 mg, 2.00 mmol, 20 mol%). Then, acetonitrile (50 mL), HCI (4.0 M in 1,4-dioxane, 5.0 mL, 20 mmol, 2.0 equiv.), and SO2 (3.0 M in MeCN, 32 mL, 0.10 mol, 10 equiv.) were added, the vessel was quickly sealed and the mixture stirred for 5 min at 23 °C. Subsequently, iron(lll) nitrate nonahydrate (4.04 g, 10.0 mmol, 1.00 equiv.) was added to the suspension and the pressure tube was quickly resealed. A blast shield was placed in front of the set up and the mixture was then stirred at 40 °C for 18 h. After cooling to 23 °C, the resulting mixture was transferred to a 100 mL round-bottomed flask and concentrated by rotary evaporation under reduced pressure. The residue was diluted with water (50 mL) and extracted with EtOAc (3 x 75 mL). The organic layers were concentrated in a 250 mL round-bottomed flask by rotary evaporation under reduced pressure. DCM (50 mL) and a Teflon-coated magnetic stir bar were added, followed by pyrrolidine (3.31 mL, 2.84 g, 40.0 mmol, 4.00 equiv.). The pressure tube was sealed and the mixture stirred for 1 h at 23 °C. Subsequently, the mixture was transferred to a 250 mL separatory funnel and water (50 mL) was added, the aqueous phase decanted and further extracted with DCM (3 x 50 mL). The combined organic layers were dried over MgSCL, filtered, and the solvent evaporated by rotary evaporation under reduced pressure. Subsequently, CDCI3 (5 mL) and 1,3,5-trimethoxybenzene (1.68 g, 10.0 mmol, 1.00 equiv.) as internal standard were added. A 0.5 mL aliquot was taken and the yield determined to be 68 % by1H NMR spectroscopy at 500 MHz and 298 K by comparing the integration of the 1,3,5-trimethoxybenzene signal at 6.06 ppm (s, 3H) to the signal of 18 at 7.62 ppm (t, 7.6 Hz, 1H).
[0296] Rf = 0.28 (EtOAc in cyclohexane = 20%, v / v (UV)).HRMS-EI (m / z) calc’d for C17H17N1O3S1 [M]+, 315.0924; found, 315.0929; deviation: -1.6 ppm.
[0297] 1-((6-Bromonaphthalen-2-yl)sulfonyl)pyrrolidine (19)
[0298] 1 0 equiv. Fe(NO3)3• 9H2O Br
[0299] 1 0 equiv. Na2S2O35H2O
[0300] Br 1 0 equiv. CuCI
[0301] 10 equiv. SO2(3.0 M MeCN)
[0302] [l 1 20 equiv. HCI (4.0 M Dioxan)
[0303] [I y MeCN (0.20 M),
[0304] 40 °C, 16 h
[0305] NH2
[0306]
[0307] Under an ambient atmosphere, to a 20-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added 6-bromnaphthalene-2-amine (111 mg, 0.500 mmol, 1.00 equiv.), Na2S2O3'5H2O (124 mg, 0.500 mmol, 1.00 equiv.) and CuCI (49.5 mg, 0.500 mmol, 1.0 equiv.). Then, acetonitrile (2.5 mL), HCI (4.0 M in 1,4-dioxane, 250 pL, 1.00 mmol, 2.0 equiv.), and SC>2(3.0 M in MeCN, 1.7 mL, 5.0 mmol, 10 equiv.) were added, the vial was quickly sealed with a septum cap and the mixture stirred for 5 min at 23 °C. Subsequently, iron(lll) nitrate nonahydrate (202 mg, 0.500 mmol, 1.00 equiv.) was added to the suspension and the vial was quickly resealed with a septum cap. The mixture was then stirred at 40 °C for 18 h. After cooling to 23 °C, the resulting mixture was concentrated by rotary evaporation under reduced pressure. The residue was diluted with water (5 mL) and extracted with DCM (3 x 5 mL). The organic layers were combined in a 20-mL borosilicate vial and a Teflon-coated magnetic stir bar was added, followed by pyrrolidine (165 pL, 142 mg, 2.00 mmol, 4.00 equiv.). The vessel was sealed with a septum cap and the mixture stirred for 1 h at 23 °C. Subsequently water (5 mL) was added, the aqueous phase decanted and further extracted with DCM (3 x 5 mL). The combined organic layers were dried over MgSCL, filtered, and the solvent evaporated under reduced pressure. The residue was purified by column chromatography on silica with ethyl acetate in cyclohexane (20%, v / v) as eluent, to give the desired sulfonamide 19 as a brown solid (69 mg, 0.35 mmol, 69%).
[0308] Rf = 0.33 (EtOAc in pentane = 20%, v / v (UV)).
[0309] HRMS-EI (m / z) calc’d for CuH^NiChSiBri [M]+, 338.9923; found, 338.9925; deviation: -0.6 ppm.2-Chloro-4-(pyrrolidin-1-ylsulfonyl)benzonitrile (20)
[0310] 1 0 equiv. Fe(NO3)39H2O
[0311] 1 0 equiv. Na2S2O3• 5H2O
[0312] 1 0 equiv. CuCI
[0313] 10 equiv. SO2(3.0 M MeCN)
[0314] 20 equiv. HCI (4.0 M Dioxan)
[0315] MeCN (0.20 M),
[0316] 40 °C, 16 h
[0317]
[0318] 20a 20, 82%
[0319] Under an ambient atmosphere, to a 20-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added 4-amino-2-chlorobenzonitrile (76.3 mg, 0.500 mmol, 1.00 equiv.), Na2S2O3'5H2O (124 mg, 0.500 mmol, 1.00 equiv.) and CuCI (49.5 mg, 0.500 mmol, 1.0 equiv.). Then, acetonitrile (2.5 mL), HCI (4.0 M in 1,4-dioxane, 250 pL, 1.00 mmol, 2.0 equiv.), and SC>2(3.0 M in MeCN, 1.7 mL, 5.0 mmol, 10 equiv.) were added, the vial was quickly sealed with a septum cap and the mixture stirred for 5 min at 23 °C. Subsequently, iron(lll) nitrate nonahydrate (202 mg, 0.500 mmol, 1.00 equiv.) was added to the suspension and the vial was quickly resealed with a septum cap. The mixture was then stirred at 40 °C for 18 h. After cooling to 23 °C, the resulting mixture was concentrated by rotary evaporation under reduced pressure. The residue was diluted with water (5 mL) and extracted with DCM (3 x 5 mL). The organic layers were combined in a 20-mL borosilicate vial and a Teflon-coated magnetic stir bar was added, followed by pyrrolidine (165 pL, 142 mg, 2.00 mmol, 4.00 equiv.). The vessel was sealed with a septum cap and the mixture stirred for 1 h at 23 °C. Subsequently water (5 mL) was added, the aqueous phase decanted and further extracted with DCM (3 x 5 mL). The combined organic layers were dried over MgSCL, filtered, and the solvent evaporated under reduced pressure. The residue was purified by column chromatography on silica with ethyl acetate in pentane (12%, v / v) as eluent, to give the desired sulfonamide 20 as an off-white solid (87 mg, 0.41 mmol, 82%).
[0320] Rf = 0.34 (EtOAc in pentane = 30%, v / v (UV)).
[0321] HRMS-EI (m / z) calc’d forCnHnN2O2SiCli [M]+, 270.0224; found, 270.0226; deviation: -0.8 ppm.4-(Pyrrolidin-1-ylsulfonyl)trifluoromethoxybenzene (21)
[0322] 1 0 equiv. Fe(NO3)3• 9H2O
[0323] 1 0 equiv. Na2S2O3• 5H2O
[0324] 1 0 equiv. CuCI
[0325] OCF310 equiv. SO2(3.0 M MeCN)
[0326] 20 equiv. HCI (4.0 M Dioxan) 40 equiv. pyrrolidine
[0327] MeCN (020 M), DCM, 23 °C, 1 h
[0328] 40 °C, 16 h
[0329]
[0330] 21a 21, 68%
[0331] Under an ambient atmosphere, to a 20-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added 4-trifluoromethoxyaniline (88.6 mg, 0.500 mmol, 1.00 equiv.), Na2S2O3'5H2O (124 mg, 0.500 mmol, 1.00 equiv.) and CuCI (49.5 mg, 0.500 mmol, 1.0 equiv.). Then, acetonitrile (2.5 mL), HCI (4.0 M in 1,4-dioxane, 250 pL, 1.00 mmol, 2.0 equiv.), and SO2 (3.0 M in MeCN, 1.7 mL, 5.0 mmol, 10 equiv.) were added, the vial was quickly sealed with a septum cap and the mixture stirred for 5 min at 23 °C. Subsequently, iron(lll) nitrate nonahydrate (202 mg, 0.500 mmol, 1.00 equiv.) was added to the suspension and the vial was quickly resealed with a septum cap. The mixture was then stirred at 40 °C for 18 h. After cooling to 23 °C, the resulting mixture was concentrated by rotary evaporation under reduced pressure. The residue was diluted with water (5 mL) and extracted with DCM (3 x 5 mL). The organic layers were combined in a 20-mL borosilicate vial and a Teflon-coated magnetic stir bar was added, followed by pyrrolidine (165 pL, 142 mg, 2.00 mmol, 4.00 equiv.). The vessel was sealed with a septum cap and the mixture stirred for 1 h at 23 °C. Subsequently water (5 mL) was added, the aqueous phase decanted and further extracted with DCM (3 x 5 mL). The combined organic layers were dried over MgSCL, filtered, and the solvent evaporated under reduced pressure. The residue was purified by column chromatography on silica with ethyl acetate in cyclohexane (gradient, 0%-50% over 30 column volumes) as eluent, to give the desired sulfonamide 21 as a colorless solid (99 mg, 0.34 mmol, 68%).
[0332] Rf = 0.38 (EtOAc in cyclohexane = 20%, v / v (UV)).
[0333] HRMS-EI (m / z) calc’d for C11H12N1O3S1F3 [M]+, 295.0485; found, 295.0489; deviation: -1.5 ppm.1-((2-((Trifluoromethyl)thio)phenyl)sulfonyl)pyrrolidine (22)
[0334] 1 0 equiv. Fe(NO3)3• 9H2O
[0335] 1 0 equiv. Na2S2O3• 5H2O
[0336] 1 0 equiv. CuCI
[0337] 10 equiv. SO2(3.0 M MeCN)
[0338] 20 equiv. HCI (4.0 M Dioxan) xCF 40 equiv. pyrrolidine
[0339] S'3.CF, - s'CFs
[0340] S MeCN (0.20 M), DCM, 23 °C, 1 h zSs
[0341] NH240 °C, 16 hoc?° ° N °
[0342]
[0343] 22a 22, 80%
[0344] Under an ambient atmosphere, to a 20-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added 2-(trifluoromethylthio)aniline (96.6 mg, 0.500 mmol, I.OO equiv.), Na2S2O3'5H2O (124 mg, 0.500 mmol, 1.00 equiv.) and CuCI (49.5 mg, 0.500 mmol, I.O equiv.). Then, acetonitrile (2.5 mL), HCI (4.0 M in 1,4-dioxane, 250 pL, 1.00 mmol, 2.0 equiv.), and SC>2(3.0 M in MeCN, 1.7 mL, 5.0 mmol, 10 equiv.) were added, the vial was quickly sealed with a septum cap and the mixture stirred for 5 min at 23 °C. Subsequently, iron(lll) nitrate nonahydrate (202 mg, 0.500 mmol, 1.00 equiv.) was added to the suspension and the vial was quickly resealed with a septum cap. The mixture was then stirred at 40 °C for 18 h. After cooling to 23 °C, the resulting mixture was concentrated by rotary evaporation under reduced pressure. The residue was diluted with water (5 mL) and extracted with DCM (3 x 5 mL). The organic layers were combined in a 20-mL borosilicate vial and a Teflon-coated magnetic stir bar was added, followed by pyrrolidine (165 pL, 142 mg, 2.00 mmol, 4.00 equiv.). The vessel was sealed with a septum cap and the mixture stirred for 1 h at 23 °C. Subsequently water (5 mL) was added, the aqueous phase decanted and further extracted with DCM (3 x 5 mL). The combined organic layers were dried over MgSCL, filtered, and the solvent evaporated under reduced pressure. The residue was purified by column chromatography on silica with ethyl acetate in pentane (12% v / v) as eluent, to give the desired sulfonamide 22 as a yellow oil (98 mg, 0.40 mmol, 80%).
[0345] Rf = 0.47 (EtOAc in pentane = 20%, v / v (UV)).
[0346] HRMS-EI (m / z) calc’d for C11H12N1O2S2F3 [M]+, 311.0256; found, 311.0258; deviation: -0.6 ppm.
[0347] 3-Bromo-4-(pyrrolidin-1-ylsulfonyl)benzonitrile (23)
[0348] 1 0 equiv. Fe(NO3)3■ 9H2O
[0349] 1 0 equiv. Na2S2O3■ 5H2O
[0350] 1 0 equiv. CuCI
[0351] 10 equiv. SO2(30 M MeCN)
[0352] 20 equiv. HCI (40 M Dioxan) 40 equiv. pyrrolidine
[0353] MeCN (020 M), DCM, 23 °C, 1 h
[0354] 40 °C, 16 h
[0355]
[0356] 23aUnder an ambient atmosphere, to a 20-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added 4-amino-3-bromobenzonitrile (98.5 mg, 0.500 mmol, I.OO equiv.), Na2S2O3'5H2O (124 mg, 0.500 mmol, 1.00 equiv.) and CuCI (49.5 mg, 0.500 mmol, I.O equiv.). Then, acetonitrile (2.5 mL), HCI (4.0 M in 1,4-dioxane, 250 pL, 1.00 mmol, 2.0 equiv.), and SC>2(3.0 M in MeCN, 1.7 mL, 5.0 mmol, 10 equiv.) were added, the vial was quickly sealed with a septum cap and the mixture stirred for 5 min at 23 °C. Subsequently, iron(lll) nitrate nonahydrate (202 mg, 0.500 mmol, 1.00 equiv.) was added to the suspension and the vial was quickly resealed with a septum cap. The mixture was then stirred at 40 °C for 18 h. After cooling to 23 °C, the resulting mixture was concentrated by rotary evaporation under reduced pressure. The residue was diluted with water (5 mL) and extracted with DCM (3 x 5 mL). The organic layers were combined in a 20-mL borosilicate vial and a Teflon-coated magnetic stir bar was added, followed by pyrrolidine (165 pL, 142 mg, 2.00 mmol, 4.00 equiv.). The vessel was sealed with a septum cap and the mixture stirred for 1 h at 23 °C. Subsequently water (5 mL) was added, the aqueous phase decanted and further extracted with DCM (3 x 5 mL). The combined organic layers were dried over MgSCL, filtered, and the solvent evaporated under reduced pressure. The residue was purified by column chromatography on silica with ethyl acetate in pentane (14%, v / v) as eluent, to give the desired sulfonamide 23 as an off-white solid (87 mg, 0.28 mmol, 55%).
[0357] Rf = 0.40 (EtOAc in pentane = 30%, v / v (UV)).
[0358] HRMS-ESI (m / z) calc’d for CiiHiiN2O2SiBriNai [M+Na]+, 336.9617; found, 336.9615; deviation: +0.7 ppm.
[0359] 1-((2-Methyl-3-nitrophenyl)sulfonyl)pyrrolidine (24)
[0360] 1 0 equiv. Fe(NO3)3■ 9H2O
[0361] 1 0 equiv. Na2S2O3■ 5H2O
[0362] 1 0 equiv. CuCI
[0363] 10 equiv. SO2(30 M MeCN)
[0364] 20 equiv. HCI (40 M Dioxan) 40 equiv. pyrrolidine
[0365] MeCN (0.20 M), DCM, 23 °C, 1 h
[0366] 40 °C, 16 h
[0367]
[0368] 24, 81% Under an ambient atmosphere, to a 20-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added 2-methyl-3-nitroaniline (76.1 mg, 0.500 mmol, 1.00 equiv.), Na2S2O3'5H2O (124 mg, 0.500 mmol, I.OO equiv.) and CuCI (49.5 mg, 0.500 mmol, I.O equiv.). Then, acetonitrile (2.5 mL), HCI (4.0 M in 1,4-dioxane, 250 pL, 1.00 mmol, 2.0 equiv.), and SO2 (3.0 M in MeCN, 1.7 mL, 5.0 mmol, 10 equiv.) were added, the vial was quickly sealed with a septum cap and the mixture stirred for 5 min at 23 °C.Subsequently, iron(lll) nitrate nonahydrate (202 mg, 0.500 mmol, 1.00 equiv.) was added to the suspension and the vial was quickly resealed with a septum cap. The mixture was then stirred at 40 °C for 18 h. After cooling to 23 °C, the resulting mixture was concentrated by rotary evaporation under reduced pressure. The residue was diluted with water (5 mL) and extracted with DCM (3 x 5 mL). The organic layers were combined in a 20-mL borosilicate vial and a Teflon-coated magnetic stir bar was added, followed by pyrrolidine (165 pL, 142 mg, 2.00 mmol, 4.00 equiv.). The vessel was sealed with a septum cap and the mixture stirred for 1 h at 23 °C. Subsequently water (5 mL) was added, the aqueous phase decanted and further extracted with DCM (3 x 5 mL). The combined organic layers were dried over MgSCL, filtered, and the solvent evaporated under reduced pressure. The residue was purified by column chromatography on silica with ethyl acetate in pentane (gradient, 0%-50% over 30 column volumes) as eluent, to give the desired sulfonamide 24 as a colorless solid (0.11 g, 0.41 mmol, 81%).
[0369] Rf = 0.28 (EtOAc in pentane = 20%, v / v (UV)).
[0370] HRMS-EI (m / z) calc’d for C11H14N2O4S1 [M]+, 270.0669; found, 270.0669; deviation: -0.4 ppm.
[0371] 4-(pyrrolidin-1-ylsulfonyl)benzenesulfonamide (25)
[0372] 1.0 equiv Fe(NO3)3• 9H2O
[0373] 1.0 equiv Na2S2O35H2O
[0374] 1.0 equiv CuCI O~.I,O
[0375] NH210 equiv SO2(30 M MeCN) ■4-° 'S'
[0376] 2.0 equiv HCI (40 M Dioxan) 4.0 equiv pyrrolidine
[0377] MeCN (0.20 M), DCM, 23 °C, 1 h
[0378] I 40 °C, 16 h
[0379] O''i''O O'l'O
[0380] NH2NH2NH2
[0381]
[0382] 25a 25. 54%
[0383] Under an ambient atmosphere, to a 20-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added sulfanilamide (59.1 mg, 0.500 mmol, 1.00 equiv.), Na2S2O3'5H2O (124 mg, 0.500 mmol, 1.00 equiv.) and CuCI (49.5 mg, 0.500 mmol, 1.0 equiv.). Then, acetonitrile (2.5 mL), HCI (4.0 M in 1,4-dioxane, 250 pL, 1.00 mmol, 2.0 equiv.), and SO2 (3.0 M in MeCN, 1.7 mL, 5.0 mmol, 10 equiv.) were added, the vial was quickly sealed with a septum cap and the mixture stirred for 5 min at 23 °C. Subsequently, iron(lll) nitrate nonahydrate (202 mg, 0.500 mmol, 1.00 equiv.) was added to the suspension and the vial was quickly resealed with a septum cap. The mixture was then stirred at 40 °C for 18 h. After cooling to 23 °C, the resulting mixture was concentrated by rotary evaporation under reduced pressure. The residue was diluted with water (5 mL) and extracted with DCM (3 x 5 mL). The organic layers were combined in a 20-mL borosilicate vial and a Teflon-coated magnetic stir bar was added, followed by pyrrolidine(165 pL, 142 mg, 2.00 mmol, 4.00 equiv.). The vessel was sealed with a septum cap and the mixture stirred for 1 h at 23 °C. Subsequently water (5 mL) was added, the aqueous phase decanted and further extracted with DCM (3 x 5 mL). The combined organic layers were dried over MgSCL, filtered, and the solvent evaporated under reduced pressure. The residue was purified by column chromatography on silica with ethyl acetate in pentane (40%, v / v) as eluent, to give the desired sulfonamide 25 as a colorless solid (78 mg, 0.27 mmol, 54%).
[0384] Rf = 0.64 (EtOAc in pentane = 70%, v / v (UV)).
[0385] HRMS-ESI (m / z) calc’d for CioH^ISfeC^Nai [M+Na]+, 313.0287; found, 313.0289; deviation: -0.5 ppm.
[0386] 1-((3,5-Dibromo-4-methylphenyl)sulfonyl)pyrrolidine (26)
[0387] 1 0 equiv. Fe(NO3)3• 9H2O
[0388] 1 0 equiv. Na2S2O3• 5H2O
[0389] 1 0 equiv. CuCI
[0390] 10 equiv. SO2(3.0 M MeCN)
[0391] 20 equiv. HCI (4.0 M Dioxan) 40 equiv. pyrrolidine
[0392] MeCN (0.20 M), DCM, 23 °C, 1 h
[0393] 40 °C, 16 h
[0394]
[0395] 26, 68% Under an ambient atmosphere, to a 20-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added 3,5-dibromo-4-methylaniline (133 mg, 0.500 mmol, 1.00 equiv.), Na2S2O3'5H2O (124 mg, 0.500 mmol, 1.00 equiv.) and CuCI (49.5 mg, 0.500 mmol, 1.0 equiv.). Then, acetonitrile (2.5 mL), HCI (4.0 M in 1,4-dioxane, 250 pL, 1.00 mmol, 2.0 equiv.), and SC>2(3.0 M in MeCN, 1.7 mL, 5.0 mmol, 10 equiv.) were added, the vial was quickly sealed with a septum cap and the mixture stirred for 5 min at 23 °C. Subsequently, iron(lll) nitrate nonahydrate (202 mg, 0.500 mmol, 1.00 equiv.) was added to the suspension and the vial was quickly resealed with a septum cap. The mixture was then stirred at 40 °C for 18 h. After cooling to 23 °C, the resulting mixture was concentrated by rotary evaporation under reduced pressure. The residue was diluted with water (5 mL) and extracted with DCM (3 x 5 mL). The organic layers were combined in a 20-mL borosilicate vial and a Teflon-coated magnetic stir bar was added, followed by pyrrolidine (165 pL, 142 mg, 2.00 mmol, 4.00 equiv.). The vessel was sealed with a septum cap and the mixture stirred for 1 h at 23 °C. Subsequently water (5 mL) was added, the aqueous phase decanted and further extracted with DCM (3 x 5 mL). The combined organic layers were dried over MgSCL, filtered, and the solvent evaporated under reduced pressure. The residue was purified by column chromatography on silica with ethyl acetate in pentane(gradient, 0%-50% over 30 column volumes) as eluent, to give the desired sulfonamide 26 as a colorless solid (0.13 g, 0.34 mmol, 68%).
[0396] Rf = 0.51 (EtOAc in pentane = 20%, v / v (UV)).
[0397] HRMS-EI (m / z) calc’d for CiiHi3NiO2SiBr2 [M]+, 380.9029; found, 380.9034; deviation: -1.4 ppm.
[0398] 4-(Pyrrolidin-1-ylsulfonyl)difluoromethoxybenzene (27)
[0399] 1 0 equiv. Fe(NO3)3• 9H2O
[0400] 1 0 equiv. Na2S2O3• 5H2O
[0401] 1 0 equiv. CuCI
[0402] 10 equiv. SO2(3.0 M MeCN)
[0403] 20 equiv. HCI (4.0 M Dioxan) 40 equiv. pyrrolidine
[0404] MeCN (0.20 M), DCM, 23 °C, 1 h
[0405] 40 °C, 16 h
[0406]
[0407] 27a 27, 60%
[0408] Under an ambient atmosphere, to a 20-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added 4-difluoromethoxyaniline (79.6 mg, 0.500 mmol, 1.00 equiv.), Na2S2O3'5H2O (124 mg, 0.500 mmol, 1.00 equiv.) and CuCI (49.5 mg, 0.500 mmol, 1.0 equiv.). Then, acetonitrile (2.5 mL), HCI (4.0 M in 1,4-dioxane, 250 pL, 1.00 mmol, 2.0 equiv.), and SO2 (3.0 M in MeCN, 1.7 mL, 5.0 mmol, 10 equiv.) were added, the vial was quickly sealed with a septum cap and the mixture stirred for 5 min at 23 °C. Subsequently, iron(lll) nitrate nonahydrate (202 mg, 0.500 mmol, 1.00 equiv.) was added to the suspension and the vial was quickly resealed with a septum cap. The mixture was then stirred at 40 °C for 18 h. After cooling to 23 °C, the resulting mixture was concentrated by rotary evaporation under reduced pressure. The residue was diluted with water (5 mL) and extracted with DCM (3 x 5 mL). The organic layers were combined in a 20-mL borosilicate vial and a Teflon-coated magnetic stir bar was added, followed by pyrrolidine (165 pL, 142 mg, 2.00 mmol, 4.00 equiv.). The vessel was sealed with a septum cap and the mixture stirred for 1 h at 23 °C. Subsequently water (5 mL) was added, the aqueous phase decanted and further extracted with DCM (3 x 5 mL). The combined organic layers were dried over MgSCL, filtered, and the solvent evaporated under reduced pressure. The residue was purified by column chromatography on silica with ethyl acetate in cyclohexane (gradient, 0%-50% over 30 column volumes) as eluent, to give the desired sulfonamide 27 as a colorless solid (82 mg, 0.30 mmol, 60%).
[0409] Rf = 0.26 (EtOAc in cyclohexane = 20%, v / v (UV)).
[0410] HRMS-EI (m / z) calc’d for C11H13N1O3S1F2 [M]+, 277.0579; found, 277.0579; deviation: -0.1 ppm.4-Methyl-7-(pyrrolidin-1-ylsulfonyl)-2 / 7-chromen-2-one (28)
[0411] 1 0 equiv. Fe(NO3)3■ 9H2O 1 0 equiv. Na2S2O3■ 5H2O 1 0 equiv. CuCI 10 equiv. SO2(3.0 M MeCN) 20 equiv. HCI (4.0 M Dioxan) MeCN (0.20 M), Me 40 °C, 16 h
[0412]
[0413] Under an ambient atmosphere, to a 20-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added 7-amino-4-methylcumarin (87.6 mg, 0.500 mmol, 1.00 equiv.), Na2S2O3'5H2O (124 mg, 0.500 mmol, 1.00 equiv.) and CuCI (49.5 mg, 0.500 mmol, 1.0 equiv.). Then, acetonitrile (2.5 mL), HCI (4.0 M in 1,4-dioxane, 250 pL, 1.00 mmol, 2.0 equiv.), and SC>2(3.0 M in MeCN, 1.7 mL, 5.0 mmol, 10 equiv.) were added, the vial was quickly sealed with a septum cap and the mixture stirred for 5 min at 23 °C. Subsequently, iron(lll) nitrate nonahydrate (202 mg, 0.500 mmol, 1.00 equiv.) was added to the suspension and the vial was quickly resealed with a septum cap. The mixture was then stirred at 40 °C for 18 h. After cooling to 23 °C, the resulting mixture was concentrated by rotary evaporation under reduced pressure. The residue was diluted with water (5 mL) and extracted with DCM (3 x 5 mL). The organic layers were combined in a 20-mL borosilicate vial and a Teflon-coated magnetic stir bar was added, followed by pyrrolidine (165 pL, 142 mg, 2.00 mmol, 4.00 equiv.). The vessel was sealed with a septum cap and the mixture stirred for 1 h at 23 °C. Subsequently water (5 mL) was added, the aqueous phase decanted and further extracted with DCM (3 x 5 mL). The combined organic layers were dried over MgSO4, filtered, and the solvent evaporated under reduced pressure. The residue was purified by column chromatography on silica with ethyl acetate in cyclohexane (gradient, 0%-100% over 30 column volumes) as eluent, to give the desired sulfonamide 28 as a colorless solid (107 mg, 0.37 mmol, 73%).
[0414] Rf = 0.27 (EtOAc in cyclohexane = 50%, v / v (UV)).
[0415] HRMS-EI (m / z) calc’d for C14H15N1O4S1 [M]+, 293.0716; found, 293.0714; deviation: +0.9 ppm.
[0416] Methyl 3-(pyrrolidin-1-ylsulfonyl)thiophene-2-carboxylate (29)
[0417] 1 0 equiv. Fe(NO3)3• 9H2O
[0418] 1 0 equiv. Na2S2O3• 5H2O
[0419] 1 0 equiv. CuCI
[0420] 10 equiv. SO2(3.0 M MeCN)
[0421] 20 equiv. HCI (4.0 M Dioxan) 40 equiv. pyrrolidine
[0422] MeCN (0.20 M), DCM, 23 °C, 1 h
[0423] 40 °C, 16 h
[0424]
[0425] 29a 29, 70%Under an ambient atmosphere, to a 20-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added methyl 3-amino-2-thiophenecarboxylate (78.6 mg, 0.500 mmol, I.OO equiv.), Na2S2O3'5H2O (124 mg, 0.500 mmol, 1.00 equiv.) and CuCI (49.5 mg, 0.500 mmol, 1.0 equiv.). Then, acetonitrile (2.5 mL), HCI (4.0 M in 1,4-dioxane, 250 pL, 1.00 mmol, 2.0 equiv.), and SC>2(3.0 M in MeCN, 1.7 mL, 5.0 mmol, 10 equiv.) were added, the vial was quickly sealed with a septum cap and the mixture stirred for 5 min at 23 °C. Subsequently, iron(lll) nitrate nonahydrate (202 mg, 0.500 mmol, I.OO equiv.) was added to the suspension and the vial was quickly resealed with a septum cap. The mixture was then stirred at 40 °C for 18 h. After cooling to 23 °C, the resulting mixture was concentrated by rotary evaporation under reduced pressure. The residue was diluted with water (5 mL) and extracted with DCM (3 x 5 mL). The organic layers were combined in a 20-mL borosilicate vial and a Teflon- coated magnetic stir bar was added, followed by pyrrolidine (165 pL, 142 mg, 2.00 mmol, 4.00 equiv.). The vessel was sealed with a septum cap and the mixture stirred for 1 h at 23 °C. Subsequently water (5 mL) was added, the aqueous phase decanted and further extracted with DCM (3 x 5 mL). The combined organic layers were dried over MgSC>4, filtered, and the solvent evaporated under reduced pressure. The residue was purified by column chromatography on silica with ethyl acetate in pentane (13%, v / v) as eluent, to give the desired sulfonamide 29 as a colorless oil (96 mg, 0.35 mmol, 70%).
[0426] Rf = 0.34 (EtOAc in pentane = 40%, v / v (UV)).
[0427] HRMS-ESI (m / z) calc’d for CioHi3Ni04S2Nai [M+Na]+, 298.0178; found, 298.0175; deviation: +1.1 ppm.
[0428] 1-((2,2-Difluorobenzo[d][1,3]dioxol-4-yl)sulfonyl)pyrrolidine (30)
[0429] 1 0 equiv. Fe(NO3)3■ 9H2O
[0430] 1 0 equiv. Na2S2O3■ 5H2O
[0431] 1 0 equiv. CuCI
[0432] 10 equiv. SO2(30 M MeCN)
[0433] 20 equiv. HCI (40 M Dioxan) 40 equiv. pyrrolidine
[0434] MeCN (0.20 M), DCM, 23 °C, 1 h
[0435] NH240 °C, 16 h
[0436]
[0437] 30, 56% Under an ambient atmosphere, to a 20-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added 2,2-difluorobenzo[d][1,3]dioxol-5-amine (86.6 mg, 0.500 mmol, I.OO equiv.), Na2S2O3'5H2O (124 mg, 0.500 mmol, I.OO equiv.) and CuCI (49.5 mg, 0.500 mmol, 1.0 equiv.). Then, acetonitrile (2.5 mL), HCI (4.0 M in 1,4-dioxane, 250 pL, 1.00 mmol, 2.0 equiv.), and SC>2(3.0 M in MeCN, 1.7 mL, 5.0 mmol, 10 equiv.) were added, the vial was quickly sealed with a septum cap and the mixture stirred for 5 min at 23°C. Subsequently, iron(lll) nitrate nonahydrate (202 mg, 0.500 mmol, I.OO equiv.) was added to the suspension and the vial was quickly resealed with a septum cap. The mixture was then stirred at 40 °C for 18 h. After cooling to 23 °C, the resulting mixture was concentrated by rotary evaporation under reduced pressure. The residue was diluted with water (5 mL) and extracted with DCM (3 x 5 mL). The organic layers were combined in a 20-mL borosilicate vial and a Teflon- coated magnetic stir bar was added, followed by pyrrolidine (165 pL, 142 mg, 2.00 mmol, 4.00 equiv.). The vessel was sealed with a septum cap and the mixture stirred for 1 h at 23 °C. Subsequently water (5 mL) was added, the aqueous phase decanted and further extracted with DCM (3 x 5 mL). The combined organic layers were dried over MgSC>4, filtered, and the solvent evaporated under reduced pressure. The residue was purified by column chromatography on silica with ethyl acetate in pentane (gradient, 0%-50% over 30 column volumes) as eluent, to give the desired sulfonamide 30 as a colorless solid (81 mg, 0.28 mmol, 56%).
[0438] Rf = 0.36 (EtOAc in pentane = 20%, v / v (UV)).
[0439] HRMS-EI (m / z) calc’d for C11H11N1O4S1F2 [M]+, 291.0371; found, 291.0372; deviation: -0.1 ppm.
[0440] Hippuric acid-derived sulfonamide 31
[0441] 1 0 equiv. Fe(NO3)3■ 9H2O 1 0 equiv. Na2S2O35H2O 1 0 equiv. CuCI 10 equiv. SO2(3.0 M MeCN) 4 0 equiv. O 2 0 equiv. HCI (4.0 M Dioxan) pyrrolidine MeCN (020 M), DCM, 23 °C, 40 °C, 16 h 1 h
[0442]
[0443] S2 Under an ambient atmosphere, to a 20-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added reduced p-aminohippuric acid S2 (97.1 mg, 0.500 mmol, I.OO equiv.), Na2S2O3'5H2O (124 mg, 0.500 mmol, I.OO equiv.) and CuCI (49.5 mg, 0.500 mmol, 1.0 equiv.). Then, acetonitrile (2.5 mL), HCI (4.0 M in 1,4-dioxane, 250 pL, 1.00 mmol, 2.0 equiv.), and SC>2(3.0 M in MeCN, 1.7 mL, 5.0 mmol, 10 equiv.) were added, the vial was quickly sealed with a septum cap and the mixture stirred for 5 min at 23 °C. Subsequently, iron(lll) nitrate nonahydrate (202 mg, 0.500 mmol, 1.00 equiv.) was added to the suspension and the vial was quickly resealed with a septum cap. The mixture was then stirred at 40 °C for 18 h. After cooling to 23 °C, the resulting mixture was concentrated by rotary evaporation under reduced pressure. The residue was diluted with water (5 mL) and extracted with DCM (3 x 5 mL). The organic layers were combined in a 20-mL borosilicate vial and a Teflon-coated magnetic stir bar was added, followed by pyrrolidine (165 pL, 142 mg, 2.00 mmol, 4.00 equiv.). The vessel was sealed with a septum cap andthe mixture stirred for 1 h at 23 °C. Subsequently water (5 mL) was added, the aqueous phase decanted and further extracted with DCM (3 x 5 mL). The combined organic layers were dried over MgSCL, filtered, and the solvent evaporated under reduced pressure. The residue was purified by column chromatography on silica with MeOH in DCM (10% + 2% AcOH, v / v) as eluent, to give the desired sulfonamide 33 as a light-yellow solid (0.12 g, 0.38 mmol, 75%).
[0444] Rf = 0.61 (MeOH in DCM = 10% + 2% AcOH, v / v (UV)).
[0445] HRMS-ESI (m / z) calc’d for C13H15N2O5S1 [M— H]“, 311.0707; found, 311.0710; deviation: -0.7 ppm.
[0446] Flutamide-derived sulfonamide 32
[0447] 1 0 equiv. Fe(NO3)3■ 9H2O 1 0 equiv. Na2S2O3■ 5H2O 1 0 equiv. CuCI 10 equiv. SO2(3.0 M MeCN) 40 equiv.
[0448] 20 equiv. HCI (4.0 M Dioxan) pyrrolidine MeCN (0.20 M), DCM, 23 °C, 40 °C, 16 h 1 h
[0449]
[0450] 32, 83% Under an ambient atmosphere, to a 20-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added reduced Flutamide 5 (123 mg, 0.500 mmol, 1.00 equiv.), Na2S2O3'5H2O (124 mg, 0.500 mmol, 1.00 equiv.) and CuCI (49.5 mg, 0.500 mmol, 1.0 equiv.). Then, acetonitrile (2.5 mL), HCI (4.0 M in 1,4-dioxane, 250 pL, 1.00 mmol, 2.0 equiv.), and SO2 (3.0 M in MeCN, 1.7 mL, 5.0 mmol, 10 equiv.) were added, the vial was quickly sealed with a septum cap and the mixture stirred for 5 min at 23 °C. Subsequently, iron(lll) nitrate nonahydrate (202 mg, 0.500 mmol, 1.00 equiv.) was added to the suspension and the vial was quickly resealed with a septum cap. The mixture was then stirred at 40 °C for 18 h. After cooling to 23 °C, the resulting mixture was concentrated by rotary evaporation under reduced pressure. The residue was diluted with water (5 mL) and extracted with DCM (3 x 5 mL). The organic layers were combined in a 20-mL borosilicate vial and a Teflon-coated magnetic stir bar was added, followed by pyrrolidine (165 pL, 142 mg, 2.00 mmol, 4.00 equiv.). The vessel was sealed with a septum cap and the mixture stirred for 1 h at 23 °C. Subsequently water (5 mL) was added, the aqueous phase decanted and further extracted with DCM (3 x 5 mL). The combined organic layers were dried over MgSCL, filtered, and the solvent evaporated under reduced pressure. The residue was purified by column chromatography on silica with ethyl acetate in pentane (25%, v / v) as eluent, to give the desired sulfonamide 32 as a light-yellow oil (0.12 g, 0.42 mmol, 83%).
[0451] Rf = 0.28 (EtOAc in pentane = 40%, v / v (UV)).HRMS-ESI (m / z) calc’d for CisH ^OsSiFsNai [M+Na]+, 387.0961; found, 387.0959; deviation: +0.3 ppm.
[0452] 5-(Pyrrolidin-1-ylsulfonyl)picolinonitrile (33)
[0453] 1 0 equiv. Fe(NO3)3■ 9H2O 1 0 equiv. Na2S2O3■ 5H2O 1 0 equiv. CuCI 10 equiv. SO2(3.0 M MeCN) 20 equiv. HCI (4.0 M Dioxan) 40 equiv. pyrrolidine MeCN (020 M), DCM, 23 °C, 1 h 40 °C, 16 h
[0454]
[0455] 33a 33, 38% Under an ambient atmosphere, to a 20-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added 5-aminopicolinonitrile (59.6 mg, 0.500 mmol, 1.00 equiv.), Na2S2O3'5H2O (124 mg, 0.500 mmol, 1.00 equiv.) and CuCI (49.5 mg, 0.500 mmol, 1.0 equiv.). Then, acetonitrile (2.5 mL), HCI (4.0 M in 1,4-dioxane, 250 pL, 1.00 mmol, 2.0 equiv.), and SO2 (3.0 M in MeCN, 1.7 mL, 5.0 mmol, 10 equiv.) were added, the vial was quickly sealed with a septum cap and the mixture stirred for 5 min at 23 °C. Subsequently, iron(lll) nitrate nonahydrate (202 mg, 0.500 mmol, 1.00 equiv.) was added to the suspension and the vial was quickly resealed with a septum cap. The mixture was then stirred at 40 °C for 18 h. After cooling to 23 °C, the resulting mixture was concentrated by rotary evaporation under reduced pressure. The residue was diluted with water (5 mL) and extracted with DCM (3 x 5 mL). The organic layers were combined in a 20-mL borosilicate vial and a Teflon-coated magnetic stir bar was added, followed by pyrrolidine (165 pL, 142 mg, 2.00 mmol, 4.00 equiv.). The vessel was sealed with a septum cap and the mixture stirred for 1 h at 23 °C. Subsequently water (5 mL) was added, the aqueous phase decanted and further extracted with DCM (3 x 5 mL). The combined organic layers were dried over MgSCL, filtered, and the solvent evaporated under reduced pressure. The residue was purified by column chromatography on silica with ethyl acetate in pentane (25%, v / v) as eluent, to give the desired sulfonamide 35 as an off-white solid (45 mg, 0.19 mmol, 38%).
[0456] Rf = 0.50 (EtOAc in pentane = 40%, v / v (UV)).
[0457] HRMS-EI (m / z) calc’d for C10H11N3O2S1 [M]+, 237.0567; found, 237.0565; deviation: +0.6 ppm.Sulfadoxin-derived sulfonyl chloride 34a
[0458] 1 0 equiv. Fe(NO3)3■ 9H2O
[0459] 1 0 equiv. Na2S2O3■ 5H2O
[0460] 1 0 equiv. CuCI
[0461] 10 equiv. SO2(3.0 M MeCN) NxN o O
[0462] 20 equiv. HCI (4.0 M Dioxan) MeO
[0463] MeCN (0.20 M),
[0464] 40 °C, 16 h
[0465]
[0466] 34a, 37% ° °
[0467] Under an ambient atmosphere, to a 20-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added Sulfadoxine S3 (155.2 mg, 0.500 mmol, 1.00 equiv.), Na2S2O3'5H2O (124 mg, 0.500 mmol, 1.00 equiv.) and CuCI (49.5 mg, 0.500 mmol, 1.0 equiv.). Then, acetonitrile (2.5 mL), HCI (4.0 M in 1,4-dioxane, 250 pL, 1.00 mmol, 2.0 equiv.), and SO2 (3.0 M in MeCN, 1.7 mL, 5.0 mmol, 10 equiv.) were added, the vial was quickly sealed with a septum cap and the mixture stirred for 5 min at 23 °C. Subsequently, iron(lll) nitrate nonahydrate (202 mg, 0.500 mmol, 1.00 equiv.) was added to the suspension and the vial was quickly resealed with a septum cap. The mixture was then stirred at 40 °C for 18 h. After cooling to 23 °C, the resulting mixture was concentrated by rotary evaporation under reduced pressure. The residue was diluted with water (5 mL) and extracted with DCM (3 x 5 mL). The combined organic layers were dried over MgSC>4, filtered, and the solvent evaporated under reduced pressure. The residue was purified by column chromatography on silica with ethyl acetate in pentane (30%, v / v) as eluent, to give the desired sulfonyl chloride 34 as a colorless solid (73 mg, 0.19 mmol, 37%).
[0468] Rf = 0.25 (EtOAc in pentane = 50%, v / v (UV)).
[0469] HRMS-ESI (m / z) calc’d for C12H11N3O6S2CI1 [M-H]’, 391.9783; found, 391.9789; deviation: +1.4 ppm.
[0470] Aniline Scope for Deaminative Fluorination
[0471] Ethyl-4- fluorobenzoate (35)
[0472] 2.0 equiv. Fe(NO3)39H2O CO2Et
[0473] 1.2 equiv. Na2S2O35H2O
[0474] 3.0 equiv. NaSbF6
[0475] n-PrCN : n-pentane (1 :1) (0.40 M),
[0476] 60 °C, 16 h F
[0477]
[0478] 35, 57%
[0479] Under an ambient atmosphere, to a 4-mL borosilicate vial equipped with a teflon-coated magnetic stir bar were added ethyl-4-aminobenzoate (16.5 mg, 0.100 mmol, 1.00 equiv.), Na2S2O3'5H2O (29.8 mg, 0.120 mmol, 1.20 equiv.), NaSbFe (77.6 mg, 0.300 mmol, 3.00 equiv.) and iron (III) nitrate nonahydrate (80.8 mg, 0.200 mmol, 2.00 equiv.). Then, butyronitrile (n-PrCN) (0.125 mL), n-pentane (0.125 mL) (0.4 M overall cone.) were added, the vial was quickly sealed with a septum cap and the reaction mixture stirred at 60 °C for 16 h. After cooling to 23 °C, the resulting mixture was passed through a pad of celite (~1.0g) by eluting with ethyl acetate (10 ml). Then, the solvent was removed under reduced pressure. The residue was purified by column chromatography on silica with ethyl acetate in pentane (1%, v / v) as eluent, to give the desired fluoroarene 35 as a colorless liquid (9.6 mg, 0.057 mmol, 57%).
[0480] Rf = 0.53 (EtOAc in pentane = 5%, v / v (UV)).
[0481] HRMS-EI (m / z) calc’d for CgHgChFi [M]+, 168.0581; found, 168.0581; deviation: -0.2 ppm.
[0482] 4-Fluoro-3,5-dimethylbenzonitrile (36)
[0483] 2 0 equiv. Fe(NO3)39H2O
[0484] 1 2 equiv. Na2S2O35H2O
[0485] 3 0 equiv. NaSbF6
[0486] n-PrCN : n-pentane (1 :1) (0.40 M), CN
[0487] 60 °C, 16 h
[0488]
[0489] 36, 66%
[0490] Under an ambient atmosphere, to a 4-mL borosilicate vial equipped with a teflon-coated magnetic stir bar were added 4-amino-3,5-dimethylbenzonitrile (73.1 mg, 0.500 mmol, I.OO equiv.), Na2S2O3'5H2O (149 mg, 0.600 mmol, 1.20 equiv.), NaSbFe (388 mg, 1.50 mmol, 3.00 equiv.) and iron (III) nitrate nonahydrate (404 mg, 1.00 mmol, 2.00 equiv.). Then, butyronitrile (n-PrCN) (0.625 mL), n-pentane (0.625 mL) (0.4 M overall cone.) were added, the vial was quickly sealed with a septum cap and the reaction mixture stirred at 60 °C for 16 h. After cooling to 23 °C, the resulting mixture was passed through a pad of celite (~2.5 g) by eluting with ethyl acetate (50 ml). Then, the solvent was removed under reduced pressure. The residue was purified by column chromatography on silica with ethyl acetate in pentane (1%, v / v) as eluent, to give the desired fluoroarene 36 as a colorless solid (49 mg, 0.33 mmol, 66%).
[0491] Rf = 0.43 (EtOAc in pentane = 5%, v / v (UV)).
[0492] HRMS-EI (m / z) calc’d for C9H8NiFi [M]+, 149.0635; found, 149.0636; deviation: -0.2 ppm.
[0493] (4-Fluorophenyl)(phenyl)methanone (37)
[0494] 2 0 equiv. Fe(NO3)39H2O
[0495] 1 2 equiv. Na2S2O3■ 5H2O
[0496] 3 0 equiv. NaSbF6
[0497] n-PrCN : n-pentane (1 :1) (040 M),
[0498]
[0499] 60 °C, 16 h 37, 52%
[0500] Under an ambient atmosphere, to a 4-mL borosilicate vial equipped with a teflon-coated magnetic stir bar were added 4-aminobenzophenone (19.7 mg, 0.100 mmol, 1.00 equiv.), Na2S2O3'5H2O (29.8 mg, 0.120 mmol, 1.20 equiv.), NaSbFe (77.6 mg, 0.300 mmol, 3.00 equiv.) and iron (III) nitrate nonahydrate (80.8 mg, 0.200 mmol, 2.00 equiv.). Then, butyronitrile (n-PrCN) (0.125 mL), n-pentane (0.125 mL) (0.4 M overall cone.) were added, the vial was quickly sealed with a septum cap and the reaction mixture stirred at 60 °C for16 h. After cooling to 23 °C, the resulting mixture was passed through a pad of celite (~1.0 g) by eluting with ethyl acetate (10 ml). Then, the solvent was removed under reduced pressure. The residue was purified by column chromatography on silica with ethyl acetate in pentane (1%, v / v) as eluent, to give the desired fluoroarene 37 as a colorless liquid (10.2 mg, 0.052 mmol, 52%).
[0501] Rf = 0.35 (EtOAc in pentane = 5%, v / v (UV)).
[0502] NMR Spectroscopy:
[0503] HRMS-EI (m / z) calc’d forCiaHgOiFi [M]+, 200.0632; found, 200.0635; deviation: -1.4 ppm.
[0504] 1,1,1 ,3,3,3-Hexafluoro-2-(4-fluorophenyl)propan-2-ol (38)
[0505] 20 equiv. Fe(NO3)39H2O f
[0506] 1 2 equiv. Na2S2O35H2O
[0507] O J 30 equiv. NaSbF6
[0508] L-OHn-PrCN : n-pentane (1 :1) (0.40 M), JU0H
[0509] F3C" XF360 °C, 16 h FJC^CFJ
[0510]
[0511] 38, 46%
[0512] Under an ambient atmosphere, to a 4-mL borosilicate vial equipped with a teflon-coated magnetic stir bar were added 2-(4-aminophenyl)-1,1,1,3,3,3-hexafluor-2-propanol (130 mg, 0.500 mmol, 1.00 equiv.), Na2S2O3'5H2O (149 mg, 0.600 mmol, 1.20 equiv.), NaSbFe (388 mg, 1.50 mmol, 3.00 equiv.) and iron (III) nitrate nonahydrate (404 mg, 1.00 mmol, 2.00 equiv.). Then, butyronitrile (n-PrCN) (0.625 mL), n-pentane (0.625 mL) (0.4 M overall cone.) were added, the vial was quickly sealed with a septum cap and the reaction mixture stirred at 60 °C for 16 h. After cooling to 23 °C, the resulting mixture was passed through a pad of celite (~2.5 g) by eluting with CH2CI2 (50 ml). Then, the solvent was removed under reduced pressure. The yield was determined by both1H NMR spectroscopy at 500 MHz dissolving the residue of the reaction mixture in 0.5 mL of CDCI3, and using CH2Br2 as internal standard (34.9 pL, 86.9 mg, 0.500 mmol, 1.00 equiv.) for1H NMR. The integration of the CH2Br2 signal at 4.94 ppm (s, 2H) was compared to the signal of 38 at 7.13 ppm (t, 2H).
[0513] Rt = 0.44 (EtOAc in pentane = 10%, v / v (UV)).
[0514] HRMS-EI(mZz) calc’d for C9H5OiF7[M]+, 262.0223; found, 269.0223; deviation: -0.1 ppm.
[0515] Note: Due to the volatility of the product the compound was not isolated. Signal at 5.30 ppm corresponds to CH2CI2; signals at 2.34 ppm, 1.68 ppm and 1.08 ppm correspond to n-PrCN.3-Fluoro-2,6-dimethylpyridine (39)
[0516] 2 0 equiv. Fe(NO3)39H2O
[0517] 1 2 equiv. Na2S2O35H2O
[0518] 5 0 equiv. AgSbF6
[0519] n-PrCN : n-pentane (1 :1) (0.40 M),
[0520] 60 °C, 16 h
[0521]
[0522] 39, 51%
[0523] Under an ambient atmosphere, to a 4-mL borosilicate vial equipped with a teflon-coated magnetic stir bar were added 3-amino-2,6-dimethylpyridine (61.1 mg, 0.500 mmol, 1.00 equiv.), Na2S2C>3-5H2O (149 mg, 0.600 mmol, 1.20 equiv.), AgSbFe (859 mg, 2.50 mmol, 5.00 equiv.) and iron (III) nitrate nonahydrate (404 mg, 1.00 mmol, 2.00 equiv.) respectively. Then, butyronitrile (n-PrCN) (0.625 mL), n-pentane (0.625 mL) (0.4 M overall cone.) were added, the vial was quickly sealed with a septum cap and the reaction mixture stirred at 60 °C for 16 h. After cooling to 23 °C, the resulting mixture was passed through a pad of celite (~2.5 g) by eluting with CH2CI2 (50 ml). Then, the solvent was removed under reduced pressure. The yield was determined by both1H NMR spectroscopy at 500 MHz dissolving the residue of the reaction mixture in 0.5 mL of CDCI3, and using CH2Br2 as internal standard (34.9 pL, 86.9 mg, 0.50 mmol, 1.0 equiv.) for1H NMR. The integration of the CH2Br2 signal at 4.93 ppm (s, 2H) was compared to the signal of 39 at 7.65 (dd, J = 8.8, 4.5 Hz, 1H).
[0524] Rf = 0.62 (CH2CI2 in MeOH = 10%, v / v (UV)).
[0525] HRMS-EI(mZz) calc’d for C7H8NiFi [M]+, 125.0635; found, 125.0636; deviation: -1.1 ppm.
[0526] Note: Due to the volatility of the product the compound was not isolated. Signal at 5.29 ppm corresponds to CH2CI2; signals at 2.42 ppm, 1.71 ppm and 1.06 ppm correspond to n-PrCN.
[0527] 4'-Chloro-2-fluoro-1 , 1 '-biphenyl (40)
[0528] 2 0 equiv. Fe(NO3)39H2O
[0529] 1 2 equiv. Na2S2O35H2O
[0530] 3 0 equiv. NaSbF6
[0531] n-PrCN : n-pentane (1 :1) (040 M),
[0532] 60 °C, 16 h
[0533]
[0534] 40, 61%
[0535] Under an ambient atmosphere, to a 4-mL borosilicate vial equipped with a teflon-coated magnetic stir bar were added 4'-chloro-(1,1'-biphenyl)-2-amine (102 mg, 0.500 mmol, 1.00 equiv.), Na2S2C>3-5H2O (149 mg, 0.600 mmol, 1.20 equiv.), NaSbFe (388 mg, 1.50 mmol, 3.00 equiv.) and iron (III) nitrate nonahydrate (404 mg, 1.00 mmol, 2.00 equiv.). Then, butyronitrile (n-PrCN) (0.625 mL), n-pentane (0.625 mL) (0.4 M overall cone.) were added, the vial was quickly sealed with a septum cap and the reaction mixture stirred at 60 °C for 16 h. After cooling to 23 °C, the resulting mixture was passed through a pad of celite (~2.5 g) by eluting with ethyl acetate (50 ml). Then, the solvent was removed under reducedpressure. The residue was purified by column chromatography on silica with pentane as eluent, to give the desired fluoroarene 40 as a colorless liquid (63 mg, 0.305 mmol, 61%). Rf= 0.67 (in pentane (UV)).
[0536] HRMS-EI (m / z) calc’d for C12H8CI1F1 [M]+, 206.0293; found, 206.0293; deviation: -0.1 ppm.
[0537] Lenalidomide-derived fluoroarene 41
[0538] 2 0 equiv. Fe(NO3)3■ 9H2O
[0539] 1 2 equiv. Na2S2O35H2O
[0540] 3 0 equiv. NaSbF6
[0541] n-PrCN : n-pentane (1 :1) (0.40 M),
[0542] 60 °C, 16 h
[0543]
[0544] 41 , 40%
[0545] Under an ambient atmosphere, to a 4-mL borosilicate vial equipped with a teflon-coated magnetic stir bar were added Lenalidomide (130 mg, 0.500 mmol, 1.00 equiv.), Na2S2O3'5H2O (149 mg, 0.600 mmol, 1.20 equiv.), NaSbFe (388 mg, 1.50 mmol, 3.00 equiv.) and iron (III) nitrate nonahydrate (404 mg, 1.00 mmol, 2.00 equiv.). Then, butyronitrile (n-PrCN) (1.25 mL) (c = 0.4 M) were added, the vial was quickly sealed with a septum cap and the reaction mixture stirred at 60 °C for 16 h. After cooling to 23 °C, the resulting mixture was passed through a pad of celite (~2.5 g) by eluting with ethyl acetate (50 ml). Then, the solvent was removed under reduced pressure. The residue was purified by column chromatography on silica with ethyl acetate in pentane (60%, v / v) as eluent, to give the desired fluoroarene 41 as a colorless liquid (52 mg, 0.198 mmol, 40%).
[0546] Rf = 0.37 (EtOAc in pentane = 80%, v / v (UV)).
[0547] HRMS-ESI (m / z) calc’d for Ci3HiiFiN2NaiO3 [M+Na]+, 285.0646; found, 285.0650; deviation: -1.7 ppm.
[0548] Aniline Scope for Deaminative Cvanation
[0549] Darunavir-derived benzonitrile 42
[0550] Me Me
[0551] 2.0 equiv Fe(NO3)3■ 9H2O
[0552] 1.2 equiv Na2SO3
[0553] 2.0 equiv CuCN MeCN (040 M),
[0554] 70 °C, 12 h
[0555]
[0556] 50% yield
[0557] Under an ambient atmosphere, to a 4-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added Darunavir (274 mg, 0.500 mmol, 1.00 equiv.), Na2SOs (75.7 mg, 0.600 mmol, 2.00 equiv.), CuCN (89.6 mg, 1.00 mmol, 2.00 equiv.) and iron (III) nitrate nonahydrate (404 mg, 1.00 mmol, 2.00 equiv.). Then, acetonitrile (MeCN) (1.25 mL,c = 0.40 M) was added. The vessel was sealed with a septum cap and heated at 70°C for 12 h in an aluminum block on a heating plate. After cooling to 23 °C, the resulting mixture was passed through a pad of celite by eluting with ethyl acetate (50 mL). Then, the solvent was evaporated by rotary evaporation under reduced pressure. The residue was purified by silica gel chromatography by eluting with EtOAc / pentane (40:60 (v / v)) to afford 139 mg (50%) of the title compound 42 as light yellow solid.
[0558] Rf = 0.72 (EtOAc in pentane = 70%, v / v (UV)).
[0559] HRMS-ESI(mZz) calc’d for C28H35O7N3NaiSi+[M+Na]+, 580.2088; found, 580.2087; deviation: -0.0 ppm.
[0560] 2-Methyl-3-nitrobenzonitrile (43)
[0561] 2 0 equiv. Fe(NO3)39H2O
[0562] 1 2 equiv. Na2SO3CN
[0563] 2 0 equiv. CuCN
[0564] MeCN (0 40 M),
[0565] 70 °C, 12 h
[0566]
[0567] 80% yield 43
[0568] Under an ambient atmosphere, to a 4-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added 2-methyl-3-nitroaniline (76.1 mg, 0.500 mmol, 1.00 equiv.), Na2SO3(75.7 mg, 0.600 mmol, 2.00 equiv.), CuCN (89.6 mg, 1.00 mmol, 2.00 equiv.) and iron (III) nitrate nonahydrate (404 mg, 1.00 mmol, 2.00 equiv.). Then, acetonitrile (MeCN) (1.25 mL, c = 0.4 M) was added. The vessel was sealed with a septum cap and heated at 70°C for 12 h in an aluminum block on a heating plate. After cooling to 23 °C, the resulting mixture was passed through a pad of celite by eluting with ethyl acetate (50 mL). Then, the solvent was evaporated by rotary evaporation under reduced pressure. The residue was purified by silica gel chromatography by eluting with EtOAc / pentane (5:95 (v / v)) to afford 65 mg (80%) of the title compound 43 as off white solid.
[0569] Rf = 0.31 (EtOAc in pentane = 10%, v / v (UV)).
[0570] HRMS-EI(mZz) calc’d for C8H6N2O2+[M]+, 162.0424; found, 162.0425; deviation: +1.1 ppm.
[0571] 2-Chloroterephthalonitrile (44)
[0572] 2 0 equiv. Fe(NO3)3■ 9H2O
[0573] 1 2 equiv. Na2SO3CN
[0574] 2 0 equiv. CuCN
[0575] MeCN (040 M),
[0576] 70 °C, 12 h
[0577] CN
[0578]
[0579] 77% yield 44
[0580] Under an ambient atmosphere, to a 4-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added 4-amino-2-chlorbenzonitrile (76.3 mg, 0.500 mmol, 1.00 equiv.), Na2SO3(75.7 mg, 0.600 mmol, 2.00 equiv.), CuCN (89.6 mg, 1.00 mmol, 2.00equiv.) and iron (III) nitrate nonahydrate (404 mg, 1.00 mmol, 2.00 equiv.). Then, acetonitrile (MeCN) (1.25 mL, c = 0.4 M) was added. The vessel was sealed with a septum cap and heated at 70°C for 12 h in an aluminum block on a heating plate. After cooling to 23 °C, the resulting mixture was passed through a pad of celite by eluting with ethyl acetate (50 mL). Then, the solvent was evaporated by rotary evaporation under reduced pressure. The residue was purified by silica gel chromatography by eluting with EtOAc / pentane (5:95 (v / v)) to afford 63 mg (77%) of the title compound 44 as off white solid.
[0581] Rf = 0.28 (EtOAc in pentane = 10%, v / v (UV)).
[0582] HRMS-EI(mZz) calc’d for C8H3N2CII+[M]+, 161.9980; found, 161.9979; deviation: +0.3 ppm.
[0583] 2-(T rifluoromethylthio)benzonitrile (45)
[0584] 2 0 equiv. Fe(NO3)39H2O
[0585] 1 2 equiv. Na2SO3
[0586] 2 0 equiv. CuCN
[0587] MeCN (0.40 M),
[0588] 70 °C, 12 h
[0589]
[0590] 81% yield 45
[0591] Under an ambient atmosphere, to a 4-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added 2-(trifluormethylthio)aniline (96.6 mg, 0.500 mmol, 1.00 equiv.), Na2SO3(75.7 mg, 0.600 mmol, 2.00 equiv.), CuCN (89.6 mg, 1.00 mmol, 2.00 equiv.) and iron (III) nitrate nonahydrate (404 mg, 1.00 mmol, 2.00 equiv.). Then, acetonitrile (MeCN) (1.25 mL, c = 0.4 M) was added. The vessel was sealed with a septum cap and heated at 70°C for 12 h in an aluminum block on a heating plate. After cooling to 23 °C, the resulting mixture was passed through a pad of celite by eluting with ethyl acetate (50 mL). Then, the solvent was evaporated by rotary evaporation under reduced pressure. The residue was purified by silica gel chromatography by eluting with EtOAc / pentane (4:96 (v / v)) to afford 82 mg (81%) of the title compound 45 as orange colored oil.
[0592] Rf = 0.30 (EtOAc in pentane = 10%, v / v (UV)).
[0593] HRMS-EI(mZz) calc’d forC8H4NiSiF3+[M]+, 203.0012; found, 203.0011; deviation: +0.1 ppm.
[0594] 6-Bromo-5-methylnicotinonitrile (46)
[0595] 2.0 equiv Fe(NO3)39H2O
[0596] 1 2 equiv Na2SO3
[0597] 2.0 equiv CuCN
[0598] MeCN (0 40 M),
[0599] 70 °C, 12 h
[0600]
[0601] 61% yield
[0602] Under an ambient atmosphere, to a 4-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added 5-amino-2-brom-3-methylpyridine (93.6 mg, 0.500 mmol, 1.00 equiv.), Na2SO3(75.7 mg, 0.600 mmol, 2.00 equiv.), CuCN (89.6 mg, 1.00 mmol, 2.00equiv.) and iron (III) nitrate nonahydrate (404 mg, 1.00 mmol, 2.00 equiv.). Then, acetonitrile (MeCN) (1.25 mL, c = 0.4 M) was added. The vessel was sealed with a septum cap and heated at 70°C for 12 h in an aluminum block on a heating plate. After cooling to 23 °C, the resulting mixture was passed through a pad of celite by eluting with ethyl acetate (50 mL). Then, the solvent was evaporated by rotary evaporation under reduced pressure. The residue was purified by silica gel chromatography by eluting with EtOAc / pentane (3:97 (v / v)) to afford 60 mg (61%) of the title compound 46 as off white solid.
[0603] Rf = 0.37 (EtOAc in pentane = 21%, v / v (UV)).
[0604] HRMS-EI(mZz) calc’d for CyHsIXLBrf [M]+, 195.9630; found, 195.9631; deviation: +0.5 ppm.
[0605] 2,2-Difluorobenzo[d][1 ,3]dioxole-5-carbonitrile (47)
[0606] 20 equiv Fe(NO3)3■ 9H2O
[0607] 1 2 equiv Na2SO3
[0608] FV°Y^120 ec’uiv CuCN
[0609] F Jk, - F' V».Jss JL.
[0610] ° NH2MeCN (040 M), ° ’CN
[0611] 70 °C, 12 h
[0612]
[0613] 52% yield V
[0614] Under an ambient atmosphere, to a 4-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added 2,2-Difluorbenzo[d][1 ,3]dioxol-5-amine (86.6 mg, 0.500 mmol, 1.00 equiv.), Na2SO3 (75.7 mg, 0.600 mmol, 2.00 equiv.), CuCN (89.6 mg, 1.00 mmol, 2.00 equiv.) iron (III) nitrate nonahydrate (404 mg, 1.00 mmol, 2.00 equiv.). Then, acetonitrile (MeCN) (1.25 mL, c = 0.4 M) was added. The vessel was sealed with a septum cap and heated at 70°C for 12 h in an aluminum block on a heating plate. After cooling to 23 °C, the resulting mixture was passed through a pad of celite by eluting with ethyl acetate (50 mL). Then, the solvent was evaporated by rotary evaporation under reduced pressure. The residue was purified by silica gel chromatography by eluting with EtOAc / pentane (1 :99 (v / v)) to afford 95 mg (52%) of the title compound 47 as a light yellow solid.
[0615] Rf = 0.53 (EtOAc in pentane = 10%, v / v (UV)).
[0616] HRMS-EI(mZz) calc’d for
[0617]
[0618] [M]+, 183.0126; found, 183.0125; deviation: -0.5 ppm.
[0619] 2,6-Dimethylterephthalonitrile (48)
[0620] 20 equiv Fe(NO3)39H2O
[0621] .. 1 2 equiv Na2SO
[0622] Me.3
[0623] Me
[0624] 20 equiv CuCN
[0625] MeCN (040 M),NC
[0626] Me 70 °C, 12 h Me
[0627]
[0628] 54% yield 48
[0629] Under an ambient atmosphere, to a 4-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added 4-amino-3,5-dimethylbenzonitrile (73.1 mg, 0.500 mmol, 1.00equiv.), Na2SOs (75.7 mg, 0.600 mmol, 2.00 equiv.), CuCN (89.6 mg, 1.00 mmol, 2.00 equiv.) and iron (III) nitrate nonahydrate (404 mg, 1.00 mmol, 2.00 equiv.). Then, acetonitrile (MeCN) (1.25 mL, c = 0.4 M) was added. The vessel was sealed with a septum cap and heated at 70°C for 12 h in an aluminum block on a heating plate. After cooling to 23 °C, the resulting mixture was passed through a pad of celite by eluting with ethyl acetate (50 mL). Then, the solvent was evaporated by rotary evaporation under reduced pressure. The residue was purified by silica gel chromatography by eluting with EtOAc / pentane (2:98 (v / v)) to afford 42 mg (54%) of the title compound 48 as off white solid.
[0630] Rf = 0.37 (EtOAc in pentane = 10%, v / v (UV)).
[0631] HRMS-EI(mZz) calc’d for CioHsN2+ [M]+, 128.0369; found, 128.0368; deviation: -0.8 ppm.
[0632] Flutamide-derived benzonitrile 49
[0633] 2.0 equiv Fe(NO3)39H2O
[0634] 1.2 equiv Na2SO3
[0635] 2.0 equiv CuCN
[0636] MeCN (040 M),
[0637] 70 °C, 12 h
[0638]
[0639] S1 79% yield
[0640] Under an ambient atmosphere, to a 4-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added reduced Flutamide S1 (123 mg, 0.500 mmol, 1.00 equiv.), Na2SC>3 (75.7 mg, 0.600 mmol, 2.00 equiv.), CuCN (89.6 mg, 1.00 mmol, 2.00 equiv.) and iron (III) nitrate nonahydrate (404 mg, 1.00 mmol, 2.00 equiv.). Then, acetonitrile (MeCN) (1.25 mL, c = 0.4 M) was added. The vessel was sealed with a septum cap and heated at 70°C for 12 h in an aluminum block on a heating plate. After cooling to 23 °C, the resulting mixture was passed through a pad of celite by eluting with ethyl acetate (50 mL). Then, the solvent was evaporated by rotary evaporation under reduced pressure. The residue was purified by silica gel chromatography by eluting with EtOAc / pentane (25:75 (v / v)) to afford 101 mg (79%) of the title compound 49 as yellow colored solid.
[0641] Rf = 0.41 (EtOAc in pentane = 40%, v / v (UV)).
[0642] HRMS-EI(mZz) calc’d for CI2HIIN20IF3+[M]+, 256.0817; found, 256.0814; deviation: -1.5 ppm.
[0643] Ethyl 4-cyanobenzoate (50)
[0644] 20 equiv Fe(NO3)39H2O
[0645] 1 2 equiv Na2SO3
[0646] 20 equiv CuCN
[0647] MeCN (040 M),
[0648] 70 °C, 12 h
[0649]
[0650] 69% yield 50Under an ambient atmosphere, to a 4-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added ethyl-4-aminobenzoate (82.6 mg, 0.500 mmol, 1.00 equiv.), Na2SC>3 (75.7 mg, 0.600 mmol, 2.00 equiv.), CuCN (89.6 mg, 1.00 mmol, 2.00 equiv.) and iron (III) nitrate nonahydrate (404 mg, 1.00 mmol, 2.00 equiv.). Then, acetonitrile (MeCN) (1.25 mL, c = 0.4 M) was added. The vessel was sealed with a septum cap and heated at 70°C for 12 h in an aluminum block on a heating plate. After cooling to 23 °C, the resulting mixture was passed through a pad of celite by eluting with ethyl acetate (50 mL). Then, the solvent was evaporated by rotary evaporation under reduced pressure. The residue was purified by silica gel chromatography by eluting with EtOAc / pentane (1 :99 (v / v)) to afford 60 mg (69%) of the title compound 50 as orange colored solid.
[0651] Rf = 0.58 (EtOAc in pentane = 10%, v / v (UV)).
[0652] HRMS-EI(mZz) calc’d for C7H2NiBr3+[M]+, 175.0627; found, 175.0625; deviation: +1.4 ppm.
[0653] 4-(1 , 1 , 1 ,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)benzonitrile (51)
[0654] 20 equiv. Fe(NO3)39H2O
[0655] -| 2 equiv. Na2SO39^
[0656] 20 equiv. CuCN
[0657] T on MeCN (0.40 M), I nn
[0658] J<OH70 °C, 12 h J<OH
[0659] F3C CF3F3C CF3
[0660]
[0661] 67% yield 51
[0662] Under an ambient atmosphere, to a 4-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added 2-(4-aminophenyl)-1,1,1,3,3,3-hexafluor-2-propanol (130 mg, 0.500 mmol, 1.00 equiv.), Na2SO3(75.7 mg, 0.600 mmol, 2.00 equiv.), CuCN (89.6 mg, 1.00 mmol, 2.00 equiv.) and iron (III) nitrate nonahydrate (404 mg, 1.00 mmol, 2.00 equiv.). Then, acetonitrile (MeCN) (1.25 mL, c = 0.4 M) was added. The vessel was sealed with a septum cap and heated at 70°C for 12 h in an aluminum block on a heating plate. After cooling to 23 °C, the resulting mixture was passed through a pad of celite by eluting with ethyl acetate (50 mL). Then, the solvent was evaporated by rotary evaporation under reduced pressure. The residue was purified by silica gel chromatography by eluting with EtOAc / pentane (2:98 (v / v)) to afford 90 mg (67%) of the title compound 51 as off white solid.
[0663] Rt = 0.27 (EtOAc in pentane = 10%, v / v (UV)).
[0664] HRMS-EI(mZz) calc’d for Ci0H5NiO1F6+[M]+, 269.0269; found, 269.0270; deviation: +0.0 ppm.
[0665] rac-Aminoglutethimide-derived benzonitrile rac-522.0 equiv Fe(NO3)3■ 9H2O CN
[0666] 1.2 equiv Na2SO3
[0667] 2.0 equiv CuCN
[0668] MeCN (0 40 M),
[0669] 70 °C, 12 h
[0670] H H
[0671]
[0672] rac-S2 64% yield rac-52
[0673] Under an ambient atmosphere, to a 4-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added Aminoglutethimide (rac-S2) (116 mg, 0.500 mmol, 1.00 equiv.), Na2SOs (75.7 mg, 0.600 mmol, 2.00 equiv.), CuCN (89.6 mg, 1.00 mmol, 2.00 equiv.) and iron (III) nitrate nonahydrate (404 mg, 1.00 mmol, 2.00 equiv.). Then, acetonitrile (MeCN) (1.25 mL, c = 0.4 M) was added. The vessel was sealed with a septum cap and heated at 70°C for 12 h in an aluminum block on a heating plate. After cooling to 23 °C, the resulting mixture was passed through a pad of celite by eluting with ethyl acetate (50 mL). Then, the solvent was evaporated by rotary evaporation under reduced pressure. The residue was purified by silica gel chromatography by eluting with EtOAc / pentane (25:75 (v / v)) to afford 78 mg (64%) of the title compound rac-52 as off white solid.
[0674] Rf = 0.31 (EtOAc in pentane = 40%, v / v (UV)).
[0675] HRMS-EI(mZz) calc’d forCi4Hi4N2O2[M]+, 242.1049; found, 242.1050; deviation: -0.3 ppm.
[0676] Methyl 3-cyanothiophene-2-carboxylate (53)
[0677] 2 0 equiv. Fe(NO3)39H2O
[0678] 1 2 equiv. Na2SO3
[0679] 2 0 equiv. CuCN
[0680] MeCN (040 M),
[0681] 70 °C, 12 h
[0682]
[0683] Under an ambient atmosphere, to a 4-mL borosilicate vial equipped with a Teflon-coated magnetic stir bar were added methyl 3-amino-2-thiophenecarboxylate (78.6 mg, 0.500 mmol, 1.00 equiv.), Na2SC>3 (75.7 mg, 0.600 mmol, 2.00 equiv.), CuCN (89.6 mg, 1.00 mmol, 2.00 equiv.) and iron (III) nitrate nonahydrate (404 mg, 1.00 mmol, 2.00 equiv.). Then, acetonitrile (MeCN) (1.25 mL, c = 0.4 M) was added. The vessel was sealed with a septum cap and heated at 70°C for 12 h in an aluminum block on a heating plate. After cooling to 23 °C, the resulting mixture was passed through a pad of celite by eluting with ethyl acetate (50 mL). Then, the solvent was evaporated by rotary evaporation under reduced pressure. The residue was purified by silica gel chromatography by eluting with EtOAc / pentane (10:90 (v / v)) to afford 55 mg (66%) of the title compound 53 as off white solid.
[0684] Rf = 0.25 (EtOAc in pentane = 20%, v / v (UV)).
[0685] HRMS-EI(mZz) calc’d for C7H5NIO2SI+[M]+, 167.0035; found, 167.0037; deviation: +1.4 ppm.Summary
[0686] As detailed above, the present invention provides a process for preparing arylsulfonic acids and derivatives under mild conditions from aryldiazonium salts, though conventional methods often require isolation or accumulation of these potentially hazardous intermediates. Herein the inventors have shown that iron nitrate reduction at 25 °C enables the in situ generation of diazonium salts, which allows direct deaminative chlorosulfonylation, deaminative fluorination, and deaminative cyanation from anilines and primary amino heterocycles via aryl or heteroaryl diazonium salts as fleeting intermediates. Other sulfonic acid derivatives, such as sulfonamides, sulfonyl fluorides, and sulfonic acids are readily accessible from this method.
[0687] In conclusion, the inventors have demonstrated that inexpensive Fe(NO3)3'9H2O can generate NO2 through nitrate reduction with thiosulfate at room temperature (25 °C) which enables the use of the nitrate reduction strategy for the in situ generation of aryl diazonium salts below 85 °C. The iron nitrate reduction was utilized for the deaminative chlorosulfonylation of a variety of structurally and electronically diverse anilines and amino heterocycles, giving access to multiple sulfur-based functional groups directly from the corresponding aromatic amines, without accumulation of the respective diazonium salt. The deaminative fluorination was presented as an additional application of the Fe-mediated nitrate reduction. The inventors expect that the iron nitrate reduction will also enable other deaminative functionalization reactions that require close to ambient temperature. Additionally, the inventors have described a deaminative sulfonic acid synthesis directly from anilines as a previously unknown transformation. Furthermore, the inventors demonstrate that iron nitrate can be reduced with several other sulfur oxygen based reductants and that deaminative cyanation can be carried out as an application.
Claims
1. Claims:
1. Process for the functionalization of an aromatic or heteroaromatic primary amino compound wherein an aromatic or heteroaromatic primary amino compound is reacted with a compound pair of Fe(lll) nitrate and a sulfur oxygen reductant or mixtures thereof, whereby an aromatic or heteroaromatic-N2+-intermediate compound is provided, which is in situ further subjected to a reaction step selected from a sulfochlorination step, a fluorination step or a cyanation step.
2. Process for the functionalization of an aromatic or heteroaromatic primary amino compound according to claim 1, wherein the sulfur-oxygen reductant is selected from alkali or ammonium salts of thiosulfuric acid, thiosulfates, polythionates, dithionates, trithionates, tetrathionates, dithionites, sulfites, bisulfites, sulfur dioxide, or metabisulfites, or mixtures thereof.
3. Process for the functionalization of an aromatic or heteroaromatic primary amino compound according to any one of the preceding claims, wherein the aromatic or heteroaromatiic primary amino compound is selected from Cs to C20 aryl or heteroaryl primary amino compounds.
4. Process for the functionalization of an aromatic or heteroaromatic primary amino compound according to any one of the preceding claims, wherein the reaction is carried out in an optionally aqueous polar aprotic solvent such as, but not limited to acetonitrile, butyronitrile, ethylacetate, chloroform, 1,2-dichloroethane, dichloromethane, acetone, or mixtures thereof.
5. Process for the functionalization of an aromatic or heteroaromatic primary amino compound according to any one of the preceding claims wherein said aromatic or heteroaromatic-N2+-intermediate compound is reacted with SO2 in the presence of a Cu(l) or Cu (II) salt or complex and a chloride source whereby a chlorosulfonylated aromatic or heteroaromatic compound is obtained.
6. Process for the functionalization of an aromatic or heteroaromatic primary amino compound according to any one of claims 1 to 4 wherein said aromatic or heteroaromatic-N2+-intermediate compound is reacted with a fluorination agent whereby a fluorinated aromatic or heteroaromatic compound is obtained.
7. Process for the functionalization of an aromatic or heteroaromatic primary amino compound according to claim 6, wherein the fluorination agent is selected from metal salts such as a silver, an ammonium or an alkali salt of tetrafluoric acid, hexafluorophosphoric acid or hexafluoric antimonic acid.
8. Process for the functionalization of an aromatic or heteroaromatic primary amino compound according to any one of the preceding claims wherein said aromatic or heteroaromatic-N2+-intermediate compound may be further reacted in a cyanation step with a Cu(l) or Cu (II) salt or complex and a cyanide source whereby a cyanated aromatic or heteroaromatic compound is obtained.
9. Use of a compound pair of Fe(lll) nitrate and a sulfur oxygen reductant or mixtures thereof for the functionalization of an aromatic or heteroaromatic primary amino compound.
10. Use according to claim 9 wherein the sulfur-oxygen reductant is selected from alkali or ammonium salts of thiosulfuric acid, thiosulfates, polythionates, dithionates, trithionates, tetrathionates, dithionites sulfites, bisulfites, sulfur dioxide, or metabisulfites, or mixtures thereof.
